BindingDB logo
myBDB logout

Search by Patent Identification


Patent: (prefix with "US" like US6078908)
PatentDataCompoundsHGNC
(for human-derived proteins)
Patent TitleOrganizationDepositionDownloads
US10766893 768 242 HGNC:8775 HGNC:8774 HGNC:8776 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors H. Lundbeck A/S 04/26/212D 3D TSV
US10766881 246 83 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases Array Biopharma Inc. 04/26/212D 3D TSV
US10766883 18 9 HGNC:6190 HGNC:6192 Aminopyrazoles as janus kinase inhibitors Merck Sharp & Dohme Corp. 04/26/212D 3D TSV
US10766894 52 13 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Aza-indazole compounds for use in tendon and/or ligament injuries NOVARTIS AG 04/26/212D 3D TSV
US10766884 294 137 HGNC:1773 Cyclin dependent kinase inhibitors Pfizer Inc. 04/26/212D 3D TSV
US10766897 213 155 HGNC:6251 HGNC:550 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC 04/26/212D 3D TSV
US10766864 106 106 HGNC:8156 Morphinan derivatives for the treatment of neuropathic pain Nektar Therapeutics 04/26/212D 3D TSV
US10766903 245 243 HGNC:12630 Piperidine derivatives as inhibitors of ubiquitin specific protease 7 ALMAC DISCOVERY LIMITED 04/26/212D 3D TSV
US10766858 25 19 HGNC:10597 Substituted benzamides and methods of use thereof GENENTECH, INC.; XENON PHARMACEUTICALS INC. 04/26/212D 3D TSV
US10766878 63 33 HGNC:497 Sulfonylcycloalkyl carboxamide compounds Genentech, Inc. 04/26/212D 3D TSV
US10765676 43 43 HGNC:8031 Trk-inhibiting compound ONO PHARMACEUTICAL CO., LTD. 04/26/212D 3D TSV
US10766902 96 96 HGNC:12761 Wee-1 inhibiting pyrazolopyrimidinone compounds ALMAC DISCOVERY LIMITED 04/26/212D 3D TSV
US10774065 22 22 HGNC:9644 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 NOVARTIS AG 04/25/212D 3D TSV
US10772893 488 432 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT 04/25/212D 3D TSV
US10774070 79 39 HGNC:9967 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors BLUEPRINT MEDICINES CORPORATION 04/25/212D 3D TSV
US10774051 1232 1204 HGNC:8537 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. 04/25/212D 3D TSV
US10774068 200 123 HGNC:11408 HGNC:11406 Composition and methods for inhibiting mammalian sterile 20-like kinase 1 THE SCRIPPS RESEARCH INSTITUTE; UNIVERSITÄT BREMEN 04/25/212D 3D TSV
US10774069 4 3 HGNC:6666 Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making PHARMAKEA, INC. 04/25/212D 3D TSV
US10774054 16 8 HGNC:7967 FXR (NR1H4) modulating compounds Gilead Sciences, Inc. 04/25/212D 3D TSV
US10774102 106 106 HGNC:6563 Galactoside inhibitor of galectins Galecto Biotech AB 04/25/212D 3D TSV
US10774053 706 352 HIV protease inhibitors Gilead Sciences, Inc. 04/25/212D 3D TSV
US10774052 194 191 HGNC:3691 Heteroaryl compounds and uses thereof Celgene CAR LLC; Sanofi 04/25/212D 3D TSV
US10752635 54 54 HGNC:6863 Indazole compounds and uses thereof Incyte Corporation 04/25/212D 3D TSV
US10774063 26 24 HGNC:10289 Materials and method for inhibiting replication protein A and uses thereof Indiana University Research and Technology Corporation 04/25/212D 3D TSV
US10774085 105 105 HGNC:8031 Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds ARRAY BIOPHARMA INC. 04/25/212D 3D TSV
US10774071 762 381 PD-1/PD-L1 inhibitors Gilead Sciences, Inc. 04/25/212D 3D TSV
US10774056 197 71 HGNC:4852 HGNC:6251 HGNC:4854 HGNC:4853 Substituted piperazines as selective HDAC1,2 inhibitors REGENACY PHARMACEUTICALS, INC. 04/25/212D 3D TSV
US10774092 345 343 HGNC:12558 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES; SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE; YALE UNIVERSITY 04/25/212D 3D TSV
US10759805 43 43 HGNC:6871 Compounds that are ERK inhibitors Merck Sharp & Dohme Corp. 04/19/212D 3D TSV
US10759799 40 20 HGNC:4617 HGNC:3091 Indazole containing macrocycles and therapeutic uses thereof Samumed, LLC 04/19/212D 3D TSV
US10759813 222 220 HGNC:7154 Neprilysin inhibitors Theravance Biopharma R&D IP, LLC 04/19/212D 3D TSV
US10759812 26 15 HGNC:85 HGNC:84 Thienopyrimidine derivative and use thereof in medicine Sunshine Lake Pharma Co., Ltd. 04/19/212D 3D TSV
US10759793 318 106 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors Almirall, S.A. 04/18/212D 3D TSV
US10759794 172 77 HGNC:6283 HGNC:6278 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders BAYER PHARMA AKTIENGESELLSCHAFT 04/18/212D 3D TSV
US10759787 43 33 Benzofuran derivative, preparation method thereof and use thereof in medicine Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd. 04/18/212D 3D TSV
US10759796 139 138 CXCR4 inhibitors and uses thereof X4 PHARMACEUTICALS, INC. 04/18/212D 3D TSV
US10759792 26 26 CaMKII inhibitors and uses thereof The Johns Hopkins University 04/18/212D 3D TSV
US10759777 138 138 HGNC:8846 Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators Synchronicity Pharma, Inc. 04/18/212D 3D TSV
US10758530 28 20 HGNC:10435 HGNC:10431 HGNC:10430 HGNC:10432 Carboxamide derivatives useful as rsk inhibitors PHOENIX MOLECULAR DESIGNS 04/18/212D 3D TSV
US10759766 58 32 HGNC:6307 Certain chemical entities, compositions, and methods NEUPHARMA, INC. 04/18/212D 3D TSV
US10759769 46 46 HGNC:12524 Glucosylceramide synthase inhibitors for the treatment of diseases TBA 04/18/212D 3D TSV
US10759791 104 24 HGNC:7872 Mammalian and bacterial nitric oxide synthase inhibitors Northwestern University 04/18/212D 3D TSV
US10759788 6 2 HGNC:6251 HGNC:6255 Pharmaceutical uses of pyridine carboxamide derivatives JIANGSU HENGRUI MEDICINE CO., LTD.; SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. 04/18/212D 3D TSV
US10758542 530 232 HGNC:8031 HGNC:12440 Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors Array BioPharma Inc. 04/18/212D 3D TSV
US10758539 7 7 HGNC:6307 Therapeutic compounds and uses thereof Kala Pharmaceuticals, Inc. 04/18/212D 3D TSV
US10745383 8 8 1,3,5-triazine derivative and method of using same Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Lianyungang Runzhong Pharmaceutical Co., Ltd.; Centaurus Biopharma Co., Ltd. 04/13/212D 3D TSV
US10744128 140 66 HGNC:4617 HGNC:3091 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof Samumed, LLC 04/13/212D 3D TSV
US10744125 24 6 HGNC:268 HGNC:262 HGNC:263 HGNC:264 Adenosine A3 receptor modulators Palobiofarma, S.L. 04/13/212D 3D TSV
US10745392 57 19 HGNC:10593 HGNC:10585 HGNC:10596 Benzenesulfonamide compounds and their use as therapeutic agents Xenon Pharmaceuticals Inc. 04/13/212D 3D TSV
US10745401 582 190 HGNC:3023 HGNC:5286 Condensed lactam derivative SUMITOMO DAINIPPON PHARMA CO., LTD. 04/13/212D 3D TSV
US10745399 334 57 HGNC:8978 HGNC:795 HGNC:8975 HGNC:3942 HGNC:8977 HGNC:8976 Imidazolonylquinolines and the use thereof as ATM kinase inhibitors Merck Patent GmbH 04/13/212D 3D TSV
US10745388 16 16 HGNC:6863 Indazole compounds and uses thereof Incyte Corporation 04/13/212D 3D TSV
US10745380 2 2 HGNC:10894 Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies CTXT PTY LTD 04/13/212D 3D TSV
US10745410 18 18 Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents ZENJI RESEARCH LABORATORIES 04/13/212D 3D TSV
US10745364 424 420 Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease Lycera Corporation; Merck Sharp & Dohme Corp. 04/13/212D 3D TSV
US10745420 101 96 Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase Board of Regents, The University of Texas System; ChemPartner Corporation 04/13/212D 3D TSV
US10744104 41 40 HGNC:7154 Neprilysin inhibitors Theravance Biopharma R&D IP, LLC 04/12/212D 3D TSV
US10744117 5 5 HGNC:9236 PPARG modulators for the treatment of osteoporosis The Scripps Research Institute; The University of Toledo 04/12/212D 3D TSV
US10752581 86 75 HGNC:429 HGNC:433 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase Eastern Virginia Medical School; The Regents of the University of California Santa; The United States of America Department of Health; Thomas Jefferson University 04/11/212D 3D TSV
US10752632 6 6 HGNC:7056 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds Eli Lilly and Company 04/11/212D 3D TSV
US10752598 20 20 Aryldiazepine derivatives as RSV inhibitors Enanta Pharmaceuticals, Inc. 04/11/212D 3D TSV
US10752616 136 46 HGNC:9864 HGNC:9866 HGNC:9865 Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists King''s College London 04/11/212D 3D TSV
US10752604 35 20 HGNC:11037 HGNC:11036 C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same Je II Pharmaceutical Co., Ltd. 04/11/212D 3D TSV
US10752613 21 15 HGNC:12805 HGNC:17989 Compounds and their use for reducing uric acid levels Acquist LLC 04/11/212D 3D TSV
US10752588 28 27 HGNC:3023 Dopamine D2 receptor ligands The Broad Institute, Inc.; Massachusetts Institute of Technology 04/11/212D 3D TSV
US10752623 196 62 HGNC:10593 HGNC:10585 HGNC:10596 Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors Xenon Pharmaceuticals Inc. 04/11/212D 3D TSV
US10752631 37 12 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Heterocyclic compounds as FGFR inhibitors Guangzhou Innocare Pharma Tech Co., Ltd. 04/11/212D 3D TSV
US10752626 25 25 Iso-citrate dehydrogenase (IDH) inhibitor SHANGHAI METON PHARMACEUTICAL CO., LTD 04/11/212D 3D TSV
US10752592 113 38 HGNC:8156 Morphan and morphinan analogues, and methods of use ALKERMES PHARMA IRELAND LIMITED 04/11/212D 3D TSV
US10752596 153 152 Nitrogen-containing heteroaryl compound and pharmaceutical use thereof JAPAN TOBACCO INC. 04/11/212D 3D TSV
US10751335 60 28 HGNC:8156 Signaling-biased mu opioid receptor agonists THE SCRIPPS RESEARCH INSTITUTE 04/11/212D 3D TSV
US10752615 526 148 HGNC:1133 HGNC:6171 HGNC:11719 HGNC:12434 Spirocyclic containing compounds and pharmaceutical uses thereof GB005, Inc. 04/11/212D 3D TSV
US10751339 55 14 HGNC:8979 HGNC:8978 HGNC:6251 Substituted aminopyrimidine compounds and methods of use SUNSHINE LAKE PHARMA CO., LTD.; CALITOR SCIENCES, LLC 04/11/212D 3D TSV
US10738015 84 42 HGNC:8155 HGNC:8156 1,3-diaza-spiro-[3.4]-octane derivatives GRÜNENTHAL GMBH 04/04/212D 3D TSV
US10738063 246 64 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds Pfizer Inc. 04/04/212D 3D TSV
US10738007 130 97 HGNC:10251 HGNC:10252 Amide compounds as kinase inhibitors, compositions and methods of treatment Translation Drug Development, LLC 04/04/212D 3D TSV
USRE48150 34 33 HGNC:6857 Apoptosis signal-regulating kinase inhibitors Gilead Sciences, Inc. 04/04/212D 3D TSV
US10736881 141 96 HGNC:4852 HGNC:13315 Benzimidazole derivatives: preparation and pharmaceutical applications MEI Pharma, Inc. 04/04/212D 3D TSV
US10738053 42 4 HGNC:1373 HGNC:10548 Bicyclic compounds as dual ATX/CA inhibitors Hoffmann-La Roche Inc. 04/04/212D 3D TSV
US10738048 152 37 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 04/04/212D 3D TSV
US10738074 43 29 Cyclic di-nucleotide compounds as STING agonists Merck Sharp & Dohme Corp. 04/04/212D 3D TSV
US10738052 205 204 HGNC:7029 Imidazotriaines and imidazopyrimidines as kinase inhibitors INCYTE HOLDINGS CORPORATION; INCYTE CORPORATION 04/04/212D 3D TSV
US10738026 17 11 HGNC:10597 Isoquinoline derivatives and use thereof Purdue Pharma L.P. 04/04/212D 3D TSV
US10736890 75 37 HGNC:8156 Methods for treating depressive symptoms ALKERMES PHARMA IRELAND LIMITED 04/04/212D 3D TSV
US10738056 510 501 Pyrazolopyrimidinone compounds and uses thereof Aduro BioTech Inc. 04/04/212D 3D TSV
US10738009 160 158 HGNC:10582 Pyridone amides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED 04/04/212D 3D TSV
US10736974 64 35 HGNC:3788 Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy THE JOHNS HOPKINS UNIVERSITY 04/04/212D 3D TSV
US10738057 246 118 HGNC:8978 HGNC:8977 Tertiary alcohols as PI3K-γ inhibitors Incyte Corporation 04/04/212D 3D TSV
US10736883 326 315 HGNC:339 Triazole furan compounds as agonists of the APJ receptor AMGEN INC. 04/04/212D 3D TSV
US10723742 270 242 HGNC:29079 Biphenyl compound or salt thereof Taiho Pharmaceutical Co., Ltd. 03/30/212D 3D TSV
US10730902 10 5 HGNC:6561 HGNC:6563 1,1 ′-sulfanediyl-di-beta-D-galactopyranosides as inhibitors of galectins GALECTO BIOTECH AB 03/28/212D 3D TSV
US10730889 403 380 HGNC:30092 Amido spirocyclic amide and sulfonamide derivatives FORMA TM, LLC; Genentech, Inc. 03/28/212D 3D TSV
US10723734 237 230 HGNC:19679 Biaryl kinase inhibitors Bristol-Myers Squibb Company 03/28/212D 3D TSV
US10722495 51 51 HGNC:6863 Cyanoindazole compounds and uses thereof Incyte Corporation 03/28/212D 3D TSV
US10722597 33 4 HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 Cyclodextrin-panobinostat adduct MIDATECH LTD. 03/28/212D 3D TSV
US10722489 10 10 HGNC:8923 D-3-phosphoglycerate dehydrogenase allosteric inhibitor and use thereof Peking University 03/28/212D 3D TSV
US10723705 206 204 HGNC:13315 Heterocyclic compounds and uses thereof Incyte Corporation 03/28/212D 3D TSV
US10723709 26 6 HGNC:2536 HGNC:2537 HGNC:2545 Protease inhibitors MEDIVIR AB 03/28/212D 3D TSV
US10723723 220 173 HGNC:6255 Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors Bristol-Myers Squibb Company 03/28/212D 3D TSV
US10730882 34 34 HGNC:10436 2-aminoquinazoline derivatives as P70S6 kinase inhibitors SENTINEL ONCOLOGY LIMITED 03/27/212D 3D TSV
US10730880 867 199 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors Array BioPharma Inc.; Celgene Corporation 03/27/212D 3D TSV
US10730877 3210 841 HGNC:15633 HGNC:15631 HGNC:15632 4-Azaindole compounds Bristol-Myers Squibb Company 03/27/212D 3D TSV
US10730868 104 95 HGNC:3540 Bicyclic heteroaryl substituted compounds Bristol-Myers Squibb Company 03/27/212D 3D TSV
US10730870 267 140 HGNC:12687 Compounds and methods for the enhanced degradation of targeted proteins ARVINAS OPERATIONS, INC.; YALE UNIVERSITY 03/27/212D 3D TSV
US10730865 49 49 Compounds for modulating aquaporins APOGLYX AB 03/27/212D 3D TSV
US10730860 3 2 HGNC:13575 Diaminopyrimidine benzenesulfone derivatives and uses thereof Dana-Farber Cancer Institute, Inc. 03/27/212D 3D TSV
US10730881 28 28 HGNC:620 Fused pyrimidine derivatives HOFFMANN-LA ROCHE, INC. 03/27/212D 3D TSV
US10730866 84 72 HGNC:10597 Indole derivatives and use thereof Purdue Pharma L.P. 03/27/212D 3D TSV
US10730874 328 296 HGNC:6371 Inhibitors of plasma kallikrein and uses thereof Shire Human Genetic Therapies, Inc. 03/27/212D 3D TSV
US10730875 135 31 HGNC:6190 HGNC:6192 HGNC:12440 Substituted imidazo[1,2-A]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof JN Therapeutics 03/27/212D 3D TSV
US10729680 63 63 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT 03/21/212D 3D TSV
US10730832 130 130 Aliphatic prolinamide derivatives ORION OPHTHALMOLOGY LLC 03/21/212D 3D TSV
US10729684 24 12 HGNC:10597 Alkynyl dihydroquinoline sulfonamide compounds AMGEN INC. 03/21/212D 3D TSV
US10729695 29 29 HGNC:320 Amino, amido and heterocyclic compounds as modulators of RAGE activity and uses thereof The Research Foundation for the State University of New York; New York University 03/21/212D 3D TSV
US10730856 12 12 HGNC:9596 Benzimidazole derivatives as EP4 ligands BAYER PHARMA AKTIENGESELLSCHAFT 03/21/212D 3D TSV
US10730849 95 51 Benzo[b]thiophene compounds as STING agonists Merck Sharp & Dohme Corp. 03/21/212D 3D TSV
US10730863 435 427 HGNC:7967 Bridged bicyclic compounds as farnesoid X receptor modulators Bristol-Myers Squibb Company 03/21/212D 3D TSV
US10729710 17 6 HGNC:3023 HGNC:3020 Catecholamine prodrugs for use in the treatment of Parkinson's disease H. Lundbeck A/S 03/21/212D 3D TSV
US10717746 178 86 HGNC:1780 Chemical compounds ASTRAZENECA AB 03/21/212D 3D TSV
US10730853 36 17 HGNC:5184 Compounds as neuronal histamine receptor-3 antagonists and uses thereof XW LABORATORIES INC. 03/21/212D 3D TSV
US10717737 116 115 HGNC:29079 Cyclopropylamines as LSD1 inhibitors Incyte Corporation 03/21/212D 3D TSV
US10717733 462 116 HGNC:6834 HGNC:550 HGNC:6666 Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof Pharmaxis Ltd. 03/21/212D 3D TSV
US10717734 176 44 HGNC:6834 HGNC:550 HGNC:6666 Indole and azaindole haloallylamine derivative inhibitors of lysyl oxidases and uses thereof Pharmaxis Ltd. 03/21/212D 3D TSV
US10716791 42 17 HGNC:18367 HGNC:18368 Inhibitors of peptidyl arginine deiminase (PAD) enzymes and uses thereof University Health Network 03/21/212D 3D TSV
US10730826 181 68 HGNC:2531 HGNC:2538 HGNC:2527 HGNC:2536 HGNC:2547 HGNC:2537 HGNC:2545 HGNC:2535 Ketone inhibitors of lysine gingipain CORTEXYME, INC. 03/21/212D 3D TSV
US10717708 62 31 HGNC:3827 HGNC:3826 Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists Bristol-Myers Squibb Company 03/21/212D 3D TSV
US10730850 106 106 HGNC:550 Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors Boehringer Ingelheim International GmbH 03/21/212D 3D TSV
US10717738 29 29 HGNC:3529 Pyrimidinone and its derivatives inhibiting factor XIa ONO PHARMACEUTICAL CO., LTD. 03/21/212D 3D TSV
US10717742 148 137 Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH 03/21/212D 3D TSV
US10730833 9 9 HGNC:348 Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them Wisconsin Alumni Research Foundation 03/21/212D 3D TSV
US10730830 51 25 HGNC:3165 HGNC:14299 Tetrahydronaphthalene derivative ONO PHARMACEUTICAL CO., LTD. 03/21/212D 3D TSV
US10717764 402 207 Therapeutically active compounds and their methods of use Agios Pharmaceuticals, Inc. 03/21/212D 3D TSV
US10729691 118 59 HGNC:11005 Treatment of infectious diseases with glucose uptake inhibitors KADMON CORPORATION, LLC 03/21/212D 3D TSV
US10711036 87 87 HGNC:6819 MALT1 inhibitors and uses thereof Cornell University; Dana-Farber Cancer Institute, Inc.; Children''s Medical Center Corporation 03/15/212D 3D TSV
US10711006 65 28 HGNC:4840 HGNC:3697 HGNC:1057 HGNC:1133 HGNC:6193 HGNC:6171 HGNC:2444 HGNC:3765 Selective Bruton's tyrosine kinase inhibitor and use thereof HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. 03/15/212D 3D TSV
US10711007 49 49 HGNC:10894 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) Prelude Therapeutics Incorporated 03/15/212D 3D TSV
US10711020 881 783 Tricyclic sulfones as RORγ modulators Bristol-Myers Squibb Company 03/15/212D 3D TSV
US10709688 40 16 HGNC:3559 HGNC:3557 Agent for treating synucleinopathy Tohoku University; National University Corporation Okayama University 03/14/212D 3D TSV
US10710980 616 88 Aminopyridine derivatives and their use as selective ALK-2 inhibitors Novartis AG 03/14/212D 3D TSV
US10709712 2614 1072 HGNC:9829 Biaryl amide compounds as kinase inhibitors NOVARTIS AG 03/14/212D 3D TSV
US10709695 2 2 Compounds as rearranged during transfection (RET) inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 03/14/212D 3D TSV
US10709718 28 28 HGNC:2843 Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof Metabasis Therapeutics, Inc. 03/14/212D 3D TSV
US10710994 297 150 HGNC:497 Oxadiazole transient receptor potential channel inhibitors Genentech, Inc. 03/14/212D 3D TSV
US10711004 455 275 HGNC:497 Oxadiazole transient receptor potential channel inhibitors Genentech, Inc. 03/14/212D 3D TSV
US10710986 657 656 PD-1/PD-L1 inhibitors Gilead Sciences, Inc. 03/14/212D 3D TSV
US10710967 299 294 HGNC:9599 Pyrimidine derivative ASKA PHARMACEUTICAL CO., LTD. 03/14/212D 3D TSV
US10710978 234 59 HGNC:11403 HGNC:11408 HGNC:18174 HGNC:11406 STK4 inhibitors for treatment of hematologic malignancies DANA-FARBER CANCER INSTITUTE, INC.; FONDAZIONE CENTRO SAN RAFFAELE 03/14/212D 3D TSV
US10709719 42 10 HGNC:3167 HGNC:3165 Substituted bicyclic compounds Bristol-Myers Squibb Company 03/14/212D 3D TSV
US10709709 212 203 HGNC:10894 Substituted carbonucleoside derivatives useful as anticancer agents Pfizer Inc. 03/14/212D 3D TSV
US10676499 33 17 HGNC:3287 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA NOVARTIS AG 03/11/212D 3D TSV
US10676464 43 43 5-hydroxytryptamine receptor 7 activity modulators and their method of use Temple University Of The Commonwealth System of Higher Education 03/11/212D 3D TSV
US10676458 17 11 HGNC:4498 Antidiabetic bicyclic compounds Merch Sharp & Dohne Corp. Rahway 03/11/212D 3D TSV
US10676467 113 58 HGNC:3169 HGNC:3167 HGNC:3165 HGNC:14299 HGNC:3170 Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof Washington University 03/11/212D 3D TSV
US10676457 130 129 HGNC:29079 Cyclopropylamines as LSD1 inhibitors Incyte Corporation 03/11/212D 3D TSV
US10676465 188 94 HGNC:4324 GLP-1 receptor agonists and uses thereof Pfizer Inc. 03/11/212D 3D TSV
US10676479 360 118 HGNC:17101 Imidazolepyridine compounds and uses thereof Novartis AG 03/11/212D 3D TSV
US10676470 36 34 Inhibitors of lysine gingipain CORTEXYME, INC. 03/11/212D 3D TSV
US10676469 383 182 HGNC:8154 HGNC:8156 Kappa opioid receptor antagonists and products and methods related thereto BLACKTHORN THERAPEUTICS, INC.; THE SCRIPPS RESEARCH INSTITUTE 03/11/212D 3D TSV
US10676485 106 53 HGNC:6943 Macrocyclic MCL-1 inhibitors and methods of use AbbVie Inc. 03/11/212D 3D TSV
US10676460 56 3 HGNC:9077 HGNC:11283 HGNC:11584 HGNC:14552 HGNC:17967 HGNC:12434 HGNC:11724 HGNC:6735 HGNC:2451 HGNC:5465 HGNC:4617 HGNC:2459 HGNC:6112 HGNC:2457 HGNC:3767 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:6171 HGNC:11390 HGNC:12440 HGNC:1079 HGNC:1771 HGNC:1133 HGNC:6860 HGNC:7972 HGNC:6524 HGNC:1775 Quinazolines as potassium ion channel inhibitors Bristol-Myers Squibb Company 03/11/212D 3D TSV
US10676476 30 14 HGNC:3430 HGNC:5253 Small-molecule HSP90 inhibitors Sloan-Kettering Institute for Cancer Research 03/11/212D 3D TSV
US10676446 190 190 HGNC:3357 Bicyclic quinazolinone derivatives Hoffmann-La Roche Inc. 03/10/212D 3D TSV
US10676434 200 178 HGNC:1133 Carbazole derivatives Bristol-Myers Squibb Company 03/10/212D 3D TSV
US10675286 612 109 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. 03/10/212D 3D TSV
US10676433 355 196 HGNC:5992 HGNC:8537 Indole derivatives and their use in neurodegenerative diseases Merck Patent GmbH 03/10/212D 3D TSV
US10676438 16 10 HGNC:6251 KCNQ2-5 channel activator Ono Pharmaceutical Co., Ltd. 03/10/212D 3D TSV
US10676431 270 127 HGNC:3827 HGNC:3826 Phenylpyrrolidinone formyl peptide 2 receptor agonists Bristol-Myers Squibb Company 03/10/212D 3D TSV
US10675268 284 169 HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 Somatostatin receptor subtype 4 (SSTR4) agonists Centrexion Therapeutics Corporation 03/10/212D 3D TSV
US10675284 37 37 HGNC:6190 HGNC:8977 Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors Incyte Corporation 03/10/212D 3D TSV
US10703751 36 7 HGNC:6192 HGNC:6193 Amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof Leo Pharma A/S 03/08/212D 3D TSV
US10703741 26 16 HGNC:18368 Covalent inhibitors of PAD4 Padlock Therapeutics, Inc. 03/08/212D 3D TSV
US10702504 21 21 HGNC:11812 Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of use DANA-FARBER CANCER INSTITUTE, INC. 03/08/212D 3D TSV
US10703733 457 445 MCL-1 inhibitors Gilead Sciences, Inc. 03/08/212D 3D TSV
US10702498 27 15 HGNC:8154 HGNC:8156 MU opioid receptor modulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN-NÜRNBERG; THE BOARD OF TRUSTEES OFTHE LELAND STANFORD JUNIOR UNIVERSITY; THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 03/08/212D 3D TSV
US10703749 843 289 HGNC:8537 P2X7 modulators Janssen Pharmaceutica NV 03/08/212D 3D TSV
US10708263 5 1 Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV 03/08/212D 3D TSV
US10703740 14 14 HGNC:13575 Substituted benzimidazoles, their preparation and their use as pharmaceuticals Neomed Institute 03/08/212D 3D TSV
US10703755 351 337 HGNC:15631 Substituted purine derivative SUMITOMO DAINIPPON PHARMA CO., LTD. 03/08/212D 3D TSV
US10696692 374 308 HGNC:30092 Amido-benzyl sulfone and sulfoxide derivates TBA 03/02/212D 3D TSV
US10696672 157 152 HGNC:6161 Amino acid compounds and methods of use Pliant Therapeutics, Inc. 03/02/212D 3D TSV
US10696682 44 44 HGNC:1771 CDK inhibitors G1 Therapeutics, Inc. 03/02/212D 3D TSV
US10696661 70 69 HGNC:11305 Compounds Exonate Limited 03/02/212D 3D TSV
US10696638 48 43 HGNC:10251 HGNC:10252 Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE 03/02/212D 3D TSV
US10695334 98 57 HGNC:6371 HGNC:11830 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors Boehringer Ingelheim International GmbH 03/02/212D 3D TSV
US10696678 154 64 HGNC:1722 Kinase inhibitor, and preparing method and pharmaceutical use thereof GAN & LEE PHARMACEUTICALS 03/02/212D 3D TSV
US10696665 61 23 HGNC:5382 Mutant IDH1 inhibitors Eli Lilly and Company 03/02/212D 3D TSV
US10695337 794 388 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors Incyte Holdings Corporation; Incyte Corporation 03/02/212D 3D TSV
US10695347 84 40 HGNC:427 Pyrimidine derivative and use thereof HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. 03/02/212D 3D TSV
US10696660 91 36 HGNC:10251 HGNC:10252 Rho kinase inhibitors Kadmon Corporation, LLC 03/02/212D 3D TSV
US10696689 23 23 HGNC:11331 Somatostatin modulators and uses thereof CRINETICS PHARMACEUTICALS, INC. 03/02/212D 3D TSV
US10696655 125 125 HGNC:2348 Therapeutic compounds and uses thereof GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC. 03/02/212D 3D TSV
US10689373 308 149 HGNC:4849 HGNC:4848 1,2-substituted cyclopentanes as orexin receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED 02/22/212D 3D TSV
US10689345 273 269 1-cyano-pyrrolidine compounds as USP30 inhibitors Mission Therapeutics Limited 02/22/212D 3D TSV
US10689401 50 25 HGNC:934 HGNC:933 C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use Merck Sharp & Dohme Corp. 02/22/212D 3D TSV
US10689705 212 71 HGNC:3690 HGNC:3689 HGNC:3688 FGFR3 fusion gene and pharmaceutical drug targeting same Chugai Seiyaku Kabushiki Kaisha 02/22/212D 3D TSV
US10689346 302 246 HGNC:6371 Human plasma kallikrein inhibitors BioCryst Pharmaceuticals, Inc. 02/22/212D 3D TSV
US10688100 52 13 HGNC:10261 Macrocylic compounds as ROS1 kinase inhibitors Array BioPharma Inc. 02/22/212D 3D TSV
US10688093 708 647 HGNC:4037 Methods, compositions, and uses of novel Fyn kinase inhibitors TBA 02/22/212D 3D TSV
US10689357 43 43 HGNC:736 N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof NORTHEASTERN UNIVERSITY 02/22/212D 3D TSV
US10689398 91 89 HGNC:8157 OXA-Diazaspiro compounds having activity against pain ESTEVE PHARMACEUTICALS, S.A. 02/22/212D 3D TSV
USRE48059 122 64 Piperazine-substituted benzothiophenes for treatment of mental disorders Otsuka Pharmaceutical Co., Ltd. 02/22/212D 3D TSV
US10689327 30 15 HGNC:4595 HGNC:4594 Prodrug amino acid derivative TAISHO PHARMACEUTICAL CO., LTD. 02/22/212D 3D TSV
US10689339 69 69 HGNC:2545 Pyrrolidine derivatives Hoffmann-La Roche Inc. 02/22/212D 3D TSV
US10689362 508 124 HGNC:8804 HGNC:6342 HGNC:3765 Quinoxaline compounds as type III receptor tyrosine kinase inhibitors Development Center for Biotechnology 02/22/212D 3D TSV
US10689399 23 23 HGNC:9213 Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections Gilead Sciences, Inc. 02/22/212D 3D TSV
US10689369 149 127 Substituted indazole compounds as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp. 02/22/212D 3D TSV
US10689376 39 39 HGNC:3356 Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics Stingray Therapeutics, Inc.; The University of Utah 02/22/212D 3D TSV
US10689414 404 206 Therapeutically active compounds and their methods of use Agios Pharmaceuticals, Inc. 02/22/212D 3D TSV
US10689367 327 233 HGNC:339 Triazole pyridyl compounds as agonists of the APJ receptor AMGEN INC. 02/22/212D 3D TSV
US10689390 18 18 HGNC:13575 Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer JUBILANT BIOSYS LIMITED 02/22/212D 3D TSV
US10689395 14 14 HGNC:13575 Tricyclic fused pyridin-2-one derivatives and their use as BRD4 inhibitors JUBILANT BIOSYS LIMITED 02/22/212D 3D TSV
US10669240 500 242 HGNC:3091 5-substituted indazole-3-carboxamides and preparation and use thereof Samumed, LLC 02/21/212D 3D TSV
US10669246 153 115 HGNC:8803 HGNC:76 HGNC:6342 Benzothiazol compounds and methods using the same for treating neurodegenerative disorders 1ST Biotherapeutics, Inc. 02/21/212D 3D TSV
US10669268 343 306 HGNC:10548 Bicyclic derivatives Hoffmann-La Roche Inc. 02/21/212D 3D TSV
US10669289 209 104 HGNC:9542 HGNC:9545 Boronic acid derivatives MERCK PATENT GMBH 02/21/212D 3D TSV
US10669245 37 37 HGNC:2528 Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB 02/21/212D 3D TSV
US10669285 43 43 HGNC:10548 Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors Hoffmann-La Roche Inc. 02/21/212D 3D TSV
US10669276 48 48 Fused pyrimidine derivatives HOFFMANN-LA ROCHE INC. 02/21/212D 3D TSV
US10669271 94 30 HGNC:7794 HGNC:9644 Heterocyclic compounds as immunomodulators Incyte Corporation 02/21/212D 3D TSV
US10669279 372 104 HGNC:8780 HGNC:8781 HGNC:8783 Imidazopyridazine compounds Pfizer Inc. 02/21/212D 3D TSV
US10669243 10 10 Isoxazole carboxamides as irreversible SMYD inhibitors EPIZYME, INC. 02/21/212D 3D TSV
US10669296 8 4 LXR agonists and uses thereof Rgenix, Inc. 02/21/212D 3D TSV
US10669265 142 72 HGNC:6307 HGNC:8804 HGNC:9437 Pyridyl benzothiophenes as kinase inhibitors ALLERGAN, INC. 02/21/212D 3D TSV
US10669267 65 39 HGNC:8537 Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists Axxam S.P.A. 02/21/212D 3D TSV
US10669273 42 36 HGNC:6059 Use of aza-tryptanthrin derivatives as inhibitors of IDO1 and/or TDO Peking University 02/21/212D 3D TSV
US10683294 67 67 HGNC:1338 5-5 fused rings as C5a inhibitors ChemoCentryx, Inc. 02/16/212D 3D TSV
US10683295 59 29 HGNC:11526 HGNC:6251 HGNC:11527 HGNC:11528 Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Ogeda SA 02/16/212D 3D TSV
US10683291 3 3 HGNC:3165 Heterocyclic compounds for the treatment of disease OPPILAN PHARMA LTD. 02/16/212D 3D TSV
US10683290 84 80 Tricyclic compounds as anticancer agents Bristol-Myers Squibb Company 02/16/212D 3D TSV
US10683309 84 42 HGNC:12008 HGNC:20692 Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN; FORSCHUNGSVERBUND BERLIN E.V. 02/16/212D 3D TSV
US10668071 105 100 (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT 02/15/212D 3D TSV
US10667515 17 17 (S)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using Iowa State University Research Foundation, Inc. 02/15/212D 3D TSV
US10683279 71 68 HGNC:6857 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Enanta Pharmaceuticals, Inc. 02/15/212D 3D TSV
US10683289 23 23 HGNC:6857 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Enanta Pharmaceuticals, Inc. 02/15/212D 3D TSV
US10682352 117 100 HGNC:5382 Compound having mutant IDH inhibitory activity, preparation method and use thereof SHANGHAI HAIHE PHARMACEUTICAL CO., LTD.; SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES 02/15/212D 3D TSV
US10669227 24 9 HGNC:7175 HGNC:7176 HGNC:7166 HGNC:7159 Curcumin analogues as zinc chelators and their uses THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK 02/15/212D 3D TSV
US10669234 193 147 HGNC:12513 Cyanopyrrolidines as dub inhibitors for the treatment of cancer MISSION THERAPEUTICS LIMITED 02/15/212D 3D TSV
US10668167 176 62 HGNC:7978 HGNC:644 HGNC:3467 HGNC:8910 Glucocorticoid receptor agonist and immunoconjugates thereof AbbVie Inc. 02/15/212D 3D TSV
US10683287 96 45 HGNC:934 HGNC:933 Heterocyclic derivatives and their use in the treatment of neurological disorders Novartis AG 02/15/212D 3D TSV
US10669235 336 55 HGNC:8803 HGNC:3763 HGNC:6307 HGNC:8804 HGNC:3690 HGNC:3688 Indole derivatives and their use as protein kinase inhibitors RESPIVERT LIMITED 02/15/212D 3D TSV
US10668051 56 56 HGNC:25896 Modulators of calcium release-activated calcium channel RHIZEN PHARMACEUTICALS SA 02/15/212D 3D TSV
US10668033 4 4 HGNC:9602 Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. 02/15/212D 3D TSV
US10668067 135 135 HGNC:10597 Pyridine sulfonamides AMGEN INC. 02/15/212D 3D TSV
US10668094 92 21 Selective inhibitors of Alpha2-containing isoforms of Na,K-ATPase and use thereof for reduction of intraocular pressure Yeda Research and Development Co. Ltd. 02/15/212D 3D TSV
US10669239 74 68 HGNC:8031 Tetrahydronaphthyl urea derivative MOCHIDA PHARMACEUTICAL CO., LTD. 02/15/212D 3D TSV
US10660877 2542 841 HGNC:15633 HGNC:15631 HGNC:15632 Pyridyl substituted indole compounds Bristol-Myers Squibb Company 02/08/212D 3D TSV
US10662159 204 60 HGNC:3553 HGNC:17038 HGNC:21398 ABHD6 and dual ABHD6/MGL inhibitors and their uses MAKSCIENTIFIC, LLC 02/07/212D 3D TSV
US10660876 90 89 HGNC:2771 Amino compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. 02/07/212D 3D TSV
US10662184 150 83 HGNC:10593 HGNC:10585 HGNC:10596 Benzenesulfonamide compounds and their use as therapeutic agents Xenon Pharmaceuticals Inc. 02/07/212D 3D TSV
US10660898 27 27 HGNC:8972 Benzimidazole derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC 02/07/212D 3D TSV
US10662187 134 124 HGNC:6735 HGNC:1057 HGNC:1133 HGNC:3236 HGNC:6524 Bruton's tyrosine kinase inhibitors Zibo Biopolar Changsheng Pharmaceutical Co. Ltd.; Shanghai Institute of Materia Medica, Chinese Academy of Sciences 02/07/212D 3D TSV
US10662156 94 90 HGNC:6819 Guanidine derivative and medical use thereof Toray Industries, Inc. 02/07/212D 3D TSV
US10662189 84 78 HGNC:8781 PDE4 inhibitor SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD. 02/07/212D 3D TSV
US10662186 650 137 HGNC:1780 HGNC:1771 HGNC:1778 HGNC:1722 HGNC:1777 HGNC:1774 HGNC:1773 Substituted pyrimidines as cyclin-dependent kinase inhibitors SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. 02/07/212D 3D TSV
US10654833 96 90 HGNC:6857 ASK1 isoindolin-1-one inhibitors and methods of use thereof Hepatikos Therapeutics, LLC 02/01/212D 3D TSV
US10654857 68 7 HGNC:10555 Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors Hoffman-La Roche Inc. 02/01/212D 3D TSV
US10654835 207 69 Compounds and methods for inhibiting JAK Dizal (Jiangsu) Pharmaceutical Co., Ltd. 02/01/212D 3D TSV
US10654856 20 17 HGNC:15631 HGNC:15632 Method for preparing pyrrolo[3,2-D]pyrimidine compound, and intermediates thereof CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. 02/01/212D 3D TSV
US10654855 73 73 HGNC:391 Protein kinase B inhibitors AstraZeneca AB 02/01/212D 3D TSV
US10654836 40 10 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Pyrimidine derivative, method for preparing same and use thereof in medicine Zhejiang Hisun Pharmaceutical Co., Ltd. 02/01/212D 3D TSV
US10654866 44 21 HGNC:3467 Selective estrogen receptor degraders Eli Lilly and Company 02/01/212D 3D TSV
US10654853 147 145 Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors MISSION THERAPEUTICS LIMITED 02/01/212D 3D TSV
US10654860 35 31 HGNC:10252 Tricyclic rho kinase inhibitors Bristol-Myers Squibb Company 02/01/212D 3D TSV
US10653688 302 143 HGNC:4617 HGNC:3091 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof Samumed, LLC 01/31/212D 3D TSV
US10654831 85 14 HGNC:1780 HGNC:1771 HGNC:1774 HGNC:1773 HGNC:1775 Antiproliferative pyrimidine-based compounds G1 Therapeutics, Inc. 01/31/212D 3D TSV
US10654814 240 127 HGNC:4852 HGNC:14064 HGNC:13315 HGNC:4854 HGNC:4853 Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity KANCERA AB 01/31/212D 3D TSV
US10653701 103 52 HGNC:6307 HGNC:1133 HGNC:6193 HGNC:3689 HGNC:3236 HGNC:3688 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. 01/31/212D 3D TSV
US10647665 39 33 Biaryl urea derivative or salt thereof and preparation process and use for the same Fudan University 01/25/212D 3D TSV
US10647719 107 5 HGNC:10555 HGNC:1373 Bicyclic compounds as dual ATX/CA inhibitors Hoffmann-La Roche Inc. 01/25/212D 3D TSV
US10647706 40 14 HGNC:6026 HGNC:6027 Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies GALDERMA RESEARCH & DEVELOPMENT 01/25/212D 3D TSV
US10647694 45 40 HGNC:427 Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof ARROMAX PHARMATECH CO., LTD. 01/25/212D 3D TSV
US10647700 14 14 EZH2 inhibitor and use thereof TARAPEUTICS SCIENCE INC. 01/25/212D 3D TSV
US10646575 3 3 HGNC:2717 Heterocyclic degronimers for target protein degradation C4 Therapeutics, Inc. 01/25/212D 3D TSV
US10646492 366 342 HGNC:8977 Heterocyclylamines as PI3K inhibitors Incyte Corporation; Incyte Holdings Corporation 01/25/212D 3D TSV
US10647720 614 333 HGNC:6192 HGNC:11491 Pyrimido-pyridazinone compounds and methods of use thereof Asan BioSciences, LLC 01/25/212D 3D TSV
US10647727 66 47 HGNC:8777 Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors Merck Sharp & Dohme Corp. 01/25/212D 3D TSV
US10647686 82 50 HGNC:11396 HGNC:11395 Substituted pyrimidines for preventing or treating cancer and inflammatory diseases KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY 01/25/212D 3D TSV
US10647713 620 601 TYK2 inhibitors and uses thereof Nimbus Lakshmi, Inc. 01/25/212D 3D TSV
US10647708 46 46 HGNC:10894 Tetrahydroisoquinoline derived PRMT5-inhibitors CTXT PTY. LTD 01/25/212D 3D TSV
US10639286 194 172 Alkoxy compounds for disease treatment ACUCELA INC. 01/18/212D 3D TSV
US10640498 69 68 Compounds MISSION THERAPEUTICS LIMITED 01/18/212D 3D TSV
US10640533 114 19 HGNC:2524 HGNC:24059 HGNC:9537 Epoxyketone compounds for enzyme inhibition CENTRAX INTERNATIONAL, INC. 01/18/212D 3D TSV
US10640486 86 85 HGNC:1133 Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors Boehringer Ingelheim International GmbH 01/18/212D 3D TSV
US10640495 646 615 HGNC:8031 Heterocycle derivatives having TrkA inhibitory activity Shionogi & Co., Ltd. 01/18/212D 3D TSV
US10640503 158 158 HGNC:29079 Imidazopyridines and imidazopyrazines as LSD1 inhibitors Incyte Corporation 01/18/212D 3D TSV
US10639284 329 312 HGNC:17635 Immunomodulator compounds ChemoCentryx, Inc. 01/18/212D 3D TSV
US10640491 20 20 HGNC:1133 Inhibitors of bruton's tyrosine kinase HOFFMANN-LA ROCHE INC. 01/18/212D 3D TSV
US10640534 402 205 Therapeutically active compositions and their methods of use Agios Pharmaceuticals, Inc. 01/18/212D 3D TSV
US10633384 113 113 HGNC:10555 Diazaspirocycloalkane and azaspirocycloalkane Hoffmann-La Roche Inc. 01/12/212D 3D TSV
US10632126 676 168 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 01/10/212D 3D TSV
US10633379 264 130 Bromodomain inhibitors AbbVie Inc. 01/10/212D 3D TSV
US10633389 1029 1023 HGNC:23393 CARM1 inhibitors and uses thereof Epizyme, Inc. 01/10/212D 3D TSV
US10632122 116 115 Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases University of Washington 01/10/212D 3D TSV
US10633345 302 248 HGNC:6371 Human plasma kallikrein inhibitors BioCryst Pharmaceuticals, Inc. 01/10/212D 3D TSV
US10632171 152 130 HGNC:6932 HGNC:4479 Melanocortin receptor-specific peptides Palatin Technologies, Inc. 01/10/212D 3D TSV
US10633348 39 16 HGNC:4840 HGNC:1133 HGNC:4195 HGNC:7972 Methods to treat lymphoplasmacytic lymphoma Dana-Farber Cancer Institute, Inc. 01/10/212D 3D TSV
US10633375 111 107 HGNC:3529 Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof Jinagsu Hengrui Medicine Co., Ltd; Shanghai Hengrui Pharmaceutical Co., Ltd. 01/10/212D 3D TSV
US10633388 19 14 HGNC:4421 Pyrazolopyrimidone derivatives and methods of use thereof Shanghai Hengrui Pharmaceutical Co., ltd.; Jiangsu Hangrui Medicine Co., Ltd. 01/10/212D 3D TSV
US10633373 123 72 HGNC:6307 HGNC:8804 HGNC:9437 Pyridyl benzothiophenes as kinase inhibitors Allergan, Inc. 01/10/212D 3D TSV
US10604514 334 150 HGNC:4617 HGNC:3091 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof Samumed, LLC 12/21/202D 3D TSV
US10604534 38 19 HGNC:934 HGNC:933 C5-C6-oxacyclic fused iminothiadiazine dioxide compounds bearing an ether linker as BACE inhibitors, compositions, and their use Merck Sharp & Dohme Corp. 12/21/202D 3D TSV
US10604535 251 240 Compounds, compositions and methods Denali Therapeutics Inc. 12/21/202D 3D TSV
US10604531 11 11 HGNC:3527 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED 12/21/202D 3D TSV
US10604536 59 54 HGNC:8772 Substituted cyclopropanes as PDE-10 inhibitors Sunovion Pharamaceuticals Inc. 12/21/202D 3D TSV
US10604508 11 11 HGNC:1133 2,3-dihydro-isoindole-1-one derivative as BTK kinase suppressant, and pharmaceutical composition including same CrystalGenomics, Inc. 12/20/202D 3D TSV
US10603310 14 12 HGNC:933 2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors H. Lundbeck A/S 12/20/202D 3D TSV
US10618929 21 20 HGNC:15631 3-substituted 5-amino-6H-thiazolo[4,5-D]pyrimidine-2, 7-dione compounds for the treatment and prophylaxis of virus infection Hoffmann-La Roche Inc. 12/20/202D 3D TSV
US10618900 52 27 HGNC:4597 HGNC:4593 5-aromatic alkynyl substituted benzamide compound and preparation method, pharmaceutical composition, and use thereof Shanghai Institute of Materia Medica, Chinese Academy of Sciences 12/20/202D 3D TSV
US10618914 79 43 HGNC:11364 HGNC:11362 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-B][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity University of Pittsburgh—Of the Commonwealth System of Higher Education 12/20/202D 3D TSV
US10603330 131 65 HGNC:663 HGNC:664 Arginase inhibitors as therapeutics Mars, Incorporated 12/20/202D 3D TSV
US10618886 36 17 HGNC:5184 Compounds as neuronal histamine receptor-3 antagonists and uses thereof XW LABORATORIES INC. 12/20/202D 3D TSV
US10604489 172 171 HGNC:8156 Compounds for the treatment of pain Alkermes, Inc. 12/20/202D 3D TSV
US10603320 9 3 HGNC:10258 Compounds useful for inhibiting ROR-gamma-t Eli Lilly and Company 12/20/202D 3D TSV
US10618884 16 1 HGNC:427 Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds Suzhou Zelgen Biopharmaceuticals Co., Ltd. 12/20/202D 3D TSV
US10618912 55 18 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:8031 HGNC:8032 HGNC:8033 HGNC:427 HGNC:10261 HGNC:11397 Diaryl macrocycles as modulators of protein kinases Turning Point Therapeutics, Inc. 12/20/202D 3D TSV
US10618903 287 262 HGNC:17967 Heteroaryl substituted aminopyridine compounds Bristol-Myers Squibb Company 12/20/202D 3D TSV
US10618916 68 68 Heterocyclic compounds as immunomodulators Incyte Corporation 12/20/202D 3D TSV
US10604504 262 222 HGNC:1133 Indole carboxamide compounds Bristol-Myers Squibb Company 12/20/202D 3D TSV
US10618913 114 37 HGNC:8775 HGNC:8774 HGNC:8776 Macrocycles as PDE1 inhibitors H. Lundbeck A/S 12/20/202D 3D TSV
US10618897 168 161 HGNC:2730 Spiroindolinones as DDR1 inhibitors Hoffmann-La Roche Inc. 12/20/202D 3D TSV
US10604502 112 111 HGNC:29079 Substituted 5-cyanoindole compounds and uses thereof Novartis AG 12/20/202D 3D TSV
US10618902 256 249 HGNC:3691 Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases Celgene CAR LLC; Sanofi 12/20/202D 3D TSV
US10618910 58 29 Tricyclic heterocycles as BET protein inhibitors Incyte Corporation 12/20/202D 3D TSV
US10597383 35 35 Bicyclic proline compounds Genentech, Inc. 12/14/202D 3D TSV
US10597387 19 8 HGNC:4840 HGNC:1133 HGNC:7972 Methods to treat lymphoplasmacytic lymphoma Dana-Farber Cancer Institute, Inc. 12/14/202D 3D TSV
US10597399 40 39 HGNC:270 Substituted triazolopiperazine PARP inhibitor, preparation method therefor and use thereof Shanghai Institute of Materia Medica, Chinese Academy of Sciences 12/14/202D 3D TSV
US10597382 16 15 HGNC:6857 Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Enanta Pharmaceuticals, Inc. 12/14/202D 3D TSV
US10596172 747 259 HGNC:1079 HGNC:1133 HGNC:6193 HGNC:6171 HGNC:3236 2,4-disubstituted pyrimidines useful as kinase inhibitors Celgene CAR LLC 12/13/202D 3D TSV
US10597366 413 325 HGNC:12680 HGNC:3374 Aryl ethers and uses thereof Peloton Therapeutics, Inc. 12/13/202D 3D TSV
US10596184 158 76 HGNC:8978 HGNC:8977 Aza-heteroaryl compounds as PI3K-gamma inhibitors Incyte Corporation 12/13/202D 3D TSV
US10617673 8 8 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes Jenrin Discovery, LLC 12/13/202D 3D TSV
US10617706 43 42 HGNC:17768 Compounds for cancer chemotherapeutic sensitization REGENTS OF THE UNIVERSITY OF MINNESOTA; THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES 12/13/202D 3D TSV
US10597367 724 191 Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 12/13/202D 3D TSV
US10610125 24 5 HGNC:5382 HGNC:6541 HGNC:6535 Methods and compositions for cell-proliferation-related disorders Agios Pharmaceuticals, Inc. 12/13/202D 3D TSV
US10617692 4 4 HGNC:6192 Pyrrolopyrimidine comprising cyclopentyl substituent CENTAURUS BIOPHARMA CO.; CHIA TAI TIANQING PHARMACEUTICAL GROUP CO.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. 12/13/202D 3D TSV
US10597377 268 258 HGNC:11331 Somatostatin modulators and uses thereof CRINETICS PHARMACEUTICALS, INC. 12/13/202D 3D TSV
US10617676 596 594 HGNC:4586 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV 12/13/202D 3D TSV
US10617680 423 397 HGNC:2348 Therapeutic compounds CELGENE QUANTICEL RESEARCH, INC. 12/13/202D 3D TSV
US10617654 78 26 HGNC:286 Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas The USA, as represented by the Secretary, Department of Health and Human Services; SRI International 12/13/202D 3D TSV
US10590106 12 6 HGNC:6307 Certain chemical entities, compositions, and methods NeuPharma, Inc. 12/08/202D 3D TSV
US10590105 56 56 1,3-dihydroxy-phenyl derivatives useful as immunomodulators Bristol-Meyers Squibb Company 12/07/202D 3D TSV
US10611727 18 18 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives UNIVERSITAT DE BARCELONA; FUNACIÓ INSTITUT DE RECERCA BIOMÉDICA; IPROTEOS S.L. 12/07/202D 3D TSV
US10611730 212 212 HGNC:13628 Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators Janssen Pharmaceutica NV 12/07/202D 3D TSV
US10610539 14 14 Cardiac glycoside analogs and their use in methods for inhibition of viral infection The John Hopkins University 12/07/202D 3D TSV
US10590130 121 63 HGNC:6251 Chemical compounds AstraZeneca AB 12/07/202D 3D TSV
US10590114 215 161 HGNC:18618 Compounds, compositions, and methods Denali Therapautics Inc. 12/07/202D 3D TSV
US10611770 26 26 HGNC:427 Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. 12/07/202D 3D TSV
US10590075 29 29 Cyanopyrrolidine derivatives as inhibitors for DUBs MISSION THERAPEUTICS LIMITED 12/07/202D 3D TSV
US10611751 15 15 HGNC:3020 Dopamine D1 receptor positive allosteric modulators Eli Lilly and Company 12/07/202D 3D TSV
US10590109 85 24 Heterocyclic compounds used as FGFR inhibitors Nanjing InnoCare Pharma Tech Co., Ltd. 12/07/202D 3D TSV
US10611763 116 114 HGNC:17071 Histone demethylase inhibitors Celgene Quanticel Research, Inc. 12/07/202D 3D TSV
US10611777 156 69 HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 Imidazopyridazine compounds and their use HUTCHISON MEDIPHARMA LIMITED 12/07/202D 3D TSV
US10611728 246 97 HGNC:6251 HGNC:8157 Isoindoline compositions and methods for treating neurodegenerative disease COGNITION THERAPEUTICS, INC. 12/07/202D 3D TSV
US10590139 60 60 HGNC:8031 Method of treatment using substituted imidazo[1,2b]pyridazine compounds Array BioPharma Inc. 12/07/202D 3D TSV
US10611766 279 95 HGNC:1133 HGNC:3236 Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer Loxo Oncology Inc. 12/07/202D 3D TSV
US10590132 289 159 HGNC:6251 Selective estrogen receptor down-regulators AstraZeneca AB 12/07/202D 3D TSV
US10590077 7 7 HGNC:18083 TRPV4 antagonists GlaxoSmithKline Intellectual Property Development Limited 12/07/202D 3D TSV
US10590140 785 438 HGNC:11048 Tetrahydropyrimidodiazepine and dihydropyridodiazepine compounds for treating pain and pain related conditions ESTEVE PHARMACEUTICALS, S.A. 12/07/202D 3D TSV
US10570125 40 16 HGNC:2160 HGNC:2159 (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles Centrexion Therapeutics Corporation 11/30/202D 3D TSV
US10570116 153 53 HGNC:270 HGNC:11941 HGNC:15677 1,4-dicarbonyl-piperidyl derivatives Merck Patent GmbH 11/30/202D 3D TSV
US10568884 22 22 Compounds and compositions as protein kinase inhibitors Array BioPharma Inc. 11/30/202D 3D TSV
US10570167 249 149 HGNC:8021 Ectonucleotidase inhibitors and methods of use thereof Calithera Biosciences, Inc. 11/30/202D 3D TSV
US10570155 21 8 HGNC:9829 HGNC:1097 Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY 11/30/202D 3D TSV
US10570118 43 40 HGNC:1133 Isoquinolones as BTK inhibitors Boehringer Ingelheim International GmbH 11/30/202D 3D TSV
US10570123 100 51 HGNC:10251 HGNC:10252 Pharmacokinetically improved compounds SURFACE LOGIX, LLC 11/30/202D 3D TSV
US10570140 42 42 HGNC:29652 Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) Prelude Therapeutics Incorporated 11/30/202D 3D TSV
US10570077 7 7 HGNC:3467 Substituted (4'-hydroxyphenyl)cyclohexane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform Marquette University; Concordia University Inc. 11/30/202D 3D TSV
US10570121 412 114 HGNC:3527 Substituted dihydroisoquinolinone compounds Pfizer Inc. 11/30/202D 3D TSV
US10570156 42 42 HGNC:8772 Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS INC. 11/30/202D 3D TSV
US10570141 14 7 HGNC:1777 HGNC:1773 Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.; CENTAURUS BIOPHARMA CO., LTD.; LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. 11/30/202D 3D TSV
US10568876 141 138 HGNC:16940 Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 Merck Sharp & Dohme Corp. 11/30/202D 3D TSV
US10568888 26 13 HGNC:8781 HGNC:8783 Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors vTv Therapeutics LLC 11/30/202D 3D TSV
US10584127 26 11 HGNC:4586 HGNC:6251 HGNC:2625 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists Rugen Holdings (Cayman) Limited 11/29/202D 3D TSV
US10584111 25 22 HGNC:4597 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators Heptares Therapeutics Limited 11/29/202D 3D TSV
US10577368 81 61 HGNC:268 HGNC:262 HGNC:263 A3 adenosine receptor agonists The United States of America, as represented by the Secretary, Department of Health and Human Services; Saint Louis University 11/29/202D 3D TSV
US10584120 58 58 HGNC:9753 Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease National Health Research Institutes; Academia Sinica 11/29/202D 3D TSV
US10577374 360 356 HGNC:1133 Bruton's tyrosine kinase inhibitors Sunesis Pharmaceuticals, Inc.; Biogen MA Inc. 11/29/202D 3D TSV
US10584104 18 18 HGNC:17989 Carboxylic acid URAT1 inhibitor containing diarylmethane structure, preparation method and use thereof TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH CO., LTD. 11/29/202D 3D TSV
US10584121 10 10 Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp. 11/29/202D 3D TSV
US10584116 51 51 HGNC:497 Heterocyclic sulfonamide derivative and medicine containing same EA Pharma Co., Ltd. 11/29/202D 3D TSV
US10568874 8 8 HGNC:17635 Indane-amines as PD-L1 antagonists ChemoCentryx, Inc. 11/29/202D 3D TSV
US10583140 12 12 Ingenol analogs, pharmaceutical compositions and methods of use thereof GlaxoSmithKline Intellectual Property Development Limited 11/29/202D 3D TSV
US10584114 82 41 HGNC:9967 Inhibitors of RET BLUEPRINT MEDICINES CORPORATION 11/29/202D 3D TSV
US10577383 78 37 HGNC:7218 Macrocyclic inhibitors of myeloperoxidase Bristol-Myers Squibb Company 11/29/202D 3D TSV
US10584098 12 12 Quinolone-3-diarylethers Oregon Health & Science University 11/29/202D 3D TSV
US10584132 20 12 HGNC:10852 HGNC:10850 SHMT inhibitors The Trustees of Princeton University 11/29/202D 3D TSV
US10584103 224 211 HGNC:8039 Small molecule agonists of neurotensin receptor 1 SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 11/29/202D 3D TSV
US10584135 348 174 HGNC:3023 HGNC:3024 Substituted 3,6-diazabicyclo[3.2.0]heptanes INDIVIOR UK LIMITED 11/29/202D 3D TSV
US10577373 1366 1143 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. 11/29/202D 3D TSV
US10583137 116 56 HGNC:1165 HGNC:28923 Triazole DAGLα inhibitors THE SCRIPPS RESEARCH INSTITUTE; LEIDEN UNIVERSITY 11/29/202D 3D TSV
US10584134 79 69 HGNC:17961 Use of physiological cooling active ingredients, and agents containing such active ingredients SYMRISE AG; BASF SE 11/29/202D 3D TSV
US10561662 73 73 HGNC:19995 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139 Takeda Pharmaceutical Company Limited 11/22/202D 3D TSV
US10562893 49 22 HGNC:6171 HGNC:11719 HGNC:12434 Benzimidazoles derivatives as Tec kinases family inhibitors GB005, INC. 11/22/202D 3D TSV
US10562890 16 15 HGNC:10471 Cancer therapeutics UNIVERSITY OF VIRGINIA PATENT FOUNDATION 11/22/202D 3D TSV
US10562861 41 14 HGNC:6251 HGNC:15631 HGNC:15632 Carboxylic acid compounds Sumitomo Dainippon Pharma Co., Ltd. 11/22/202D 3D TSV
US10562853 189 63 HGNC:3023 HGNC:5286 HGNC:277 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors NEUROLIXIS; UNIVERSITE JAGELLONE 11/22/202D 3D TSV
US10562888 6 1 HGNC:3682 HGNC:3690 HGNC:3689 HGNC:3688 Crystalline FGFR4 inhibitor compound and uses thereof Eisai R&D Management Co., LTD. 11/22/202D 3D TSV
US10562878 1149 222 HGNC:11050 HGNC:11049 Cycloalkylamines as monoamine reuptake inhibitors SUNOVION PHARAMCEUTICALS INC. 11/22/202D 3D TSV
US10562844 14 14 HYPDH inhibitors and methods of use for the treatment of kidney stones Wake Forest University Health Sciences; UAB Research Foundation 11/22/202D 3D TSV
US10562850 103 100 HGNC:6371 Human plasma kallikrein inhibitors BioCryst Pharmaceuticals, Inc. 11/22/202D 3D TSV
US10562902 175 164 HGNC:17967 IRAK4 inhibitor and use thereof Beijing Hanmi Pharmaceutical Co., Ltd. 11/22/202D 3D TSV
US10562900 131 57 HGNC:6307 HGNC:3690 HGNC:3689 HGNC:3688 Indazole compounds as FGFR kinase inhibitor, preparation and use thereof Shanghai Haihe Pharmaceutical Co., Ltd.; Shanghai Institute of Materia Medica, Chinese Academy of Sciences 11/22/202D 3D TSV
US10562910 9 9 HGNC:7967 Nitrogen-containing tricyclic compounds and uses thereof in medicine NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED 11/22/202D 3D TSV
US10561656 9 5 HGNC:8775 HGNC:8774 Organic compounds INTRA-CELLULAR THERAPIES, INC. 11/22/202D 3D TSV
US10562882 43 41 Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions Takeda Pharmaceutical Company Limited 11/22/202D 3D TSV
US10562854 32 16 HGNC:1232 HGNC:12680 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS, INC. 11/22/202D 3D TSV
US10561657 26 23 HGNC:6192 Pyrrolopyrimidine compound Centaurus Biophrama Co., Ltd.; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Lianyungang Runzhong Pharmaceutical Co., Ltd. 11/22/202D 3D TSV
US10562891 435 427 Quinazolinones as PARP14 inhibitors Ribon Therapeutics Inc. 11/22/202D 3D TSV
US10561655 27 27 HGNC:9644 SHP2 inhibitors and uses thereof SYNBLia Therapeutics, Inc. 11/22/202D 3D TSV
US10562916 209 206 HGNC:8772 Substituted quinoxalines as PDE-10 inhibitors Sunovion Pharmaceuticals, Inc. 11/22/202D 3D TSV
US10562887 182 177 HGNC:10252 Triazolones and tetrazolones as inhibitors of ROCK Bristol-Myers Squibb Company 11/22/202D 3D TSV
US10577367 528 508 HGNC:17967 IRAK4 inhibiting agents BIOGEN MA INC. 11/21/202D 3D TSV
US10550117 11 11 HGNC:6853 2-azabicyclo[3.1.0]hexan-3-one derivatives and methods of use Genentech, Inc. 11/20/202D 3D TSV
US10577353 28 27 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication ViiV HEALTHCARE UK (NO.5) LIMITED 11/20/202D 3D TSV
US10577360 308 153 HGNC:8156 HGNC:1399 Arylamide derivatives having multimodal activity against pain ESTEVE PHARMACEUTICALS, S.A. 11/20/202D 3D TSV
US10577354 6 6 Bis-pyridazine compounds and their use in treating cancer Cancer Research Technology Limited 11/20/202D 3D TSV
US10577352 67 37 HGNC:3236 Cot modulators and methods of use thereof Gilead Sciences, Inc. 11/20/202D 3D TSV
US10577361 69 33 HGNC:3023 HGNC:3024 Dopamine D3 receptor antagonists having a morpholine moiety INDIVIOR UK LIMITED 11/20/202D 3D TSV
US10550140 43 43 HGNC:2771 Ether compounds for treatment of complement mediated disorders Achillion Pharmaceuticals, Inc. 11/20/202D 3D TSV
US10576087 116 58 Fused tricyclic compounds as Raf kinase inhibitors BEIGENE, LTD. 11/20/202D 3D TSV
US10550102 161 159 Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators NOVARTIS AG 11/20/202D 3D TSV
US10550127 20 20 HGNC:4498 Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes Boehringer Ingelheim International GmbH 11/20/202D 3D TSV
US10550118 56 24 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 JAK inhibitors containing a 4-membered heterocyclic amide Theravance Biopharma R&D IP, LLC 11/20/202D 3D TSV
US10550114 65 21 HGNC:391 Kinase inhibitors and their use in cancer therapy TECHNISCHE UNIVERSITÄT DORTMUND 11/20/202D 3D TSV
US10577330 196 28 HGNC:6160 HGNC:6161 HGNC:6163 HGNC:6141 HGNC:6156 Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists Saint Louis University 11/20/202D 3D TSV
US10577336 169 87 HGNC:11330 HGNC:11331 HGNC:11334 HGNC:11332 HGNC:11333 Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists Boehringer Ingelheim International GmbH 11/20/202D 3D TSV
US10544150 223 221 HGNC:11528 NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Ogeda SA 11/20/202D 3D TSV
US10550125 10 5 HGNC:2459 HGNC:2457 Prodrugs of imidazotriazine compounds as CK2 inhibitors Bristol-Myers Squibb Company 11/20/202D 3D TSV
US10550105 855 803 Pyridazinones as PARP7 inhibitors Ribon Therapeutics Inc. 11/20/202D 3D TSV
US10577308 216 36 HGNC:10588 HGNC:10596 Sodium channel modulators The Florey Institute; The University of Melbourne 11/20/202D 3D TSV
US10576064 115 107 Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH 11/20/202D 3D TSV
US10577363 985 980 Substituted piperidine compounds EPIZYME, INC. 11/20/202D 3D TSV
US10550096 5 3 HGNC:10894 Tetrahydroisoquinolines as PRMT5 inhibitors CTXT PTY LTD 11/20/202D 3D TSV
US10556883 18 9 HGNC:195 HGNC:7155 Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics GALDERMA RESEARCH & DEVELOPMENT 11/13/202D 3D TSV
US10556902 124 122 HGNC:7056 Glycosidase inhibitors Asceneuron SA 11/13/202D 3D TSV
US10556885 634 302 HGNC:4617 HGNC:3091 Isoquinolin-3-YL carboxamides and preparation and use thereof Samumed, LLC 11/13/202D 3D TSV
US10556892 65 37 HGNC:736 Piperazinyl methanone NAAA inhibitors The Regents of the University of California; Fondazione Istituto Italiano di Technologia 11/13/202D 3D TSV
US10556908 120 119 HGNC:29079 Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors Incyte Corporation 11/13/202D 3D TSV
US10556914 100 100 HGNC:4507 Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use ABBVIE INC.; ABBVIE DEUTSCHLAND GMBH & CO. KG 11/13/202D 3D TSV
US10555944 1229 556 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Eli Lilly and Company 11/13/202D 3D TSV
US10556900 75 71 HGNC:8031 TrkA kinase inhibitors, compositions and methods thereof Merck Sharp & Dohme Corp. 11/13/202D 3D TSV
US10538491 153 153 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators Vanderbilt University 11/09/202D 3D TSV
US10538523 3 3 HGNC:4076 4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain PFIZER LIMITED 11/09/202D 3D TSV
US10538528 107 46 HGNC:391 HGNC:10430 5H-pyrrolo[2,3-D]pyrimidin-6(7H)-one derivative Taiho Pahrmaceutical Co., Ltd. 11/09/202D 3D TSV
US10538497 213 208 HGNC:6059 Compounds as indoleamine 2,3-dioxygenase inhibitors Merck Sharp & Dohme Corp. 11/09/202D 3D TSV
US10538496 192 188 HGNC:19086 Methods using HDAC11 inhibitors FORMA Therapeutics, Inc.; H. Lee Moffitt Cancer Center and Research Institute, Inc. 11/09/202D 3D TSV
US10537571 140 66 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Pyrimidine FGFR4 inhibitors EISAI R&D MANAGEMENT CO., LTD. 11/09/202D 3D TSV
US10538517 40 39 HGNC:3688 Quinolone derivatives as FGFR inhibitors Principia Biopharma, Inc. 11/09/202D 3D TSV
US10538508 126 61 HGNC:17432 HGNC:1936 Substituted amino triazoles useful as human chitinase inhibitors OncoArendi Therapeutics S.A. 11/09/202D 3D TSV
US10550091 176 87 HGNC:7968 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor St. Jude Children''s Research Hospital 11/07/202D 3D TSV
US10550100 455 114 HGNC:7160 HGNC:195 HGNC:7159 HGNC:221 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis GALAPAGOS NV 11/07/202D 3D TSV
US10548313 35 34 Acetyl-CoA carboxylase modulators Monsanto Technology LLC 11/07/202D 3D TSV
US10550080 137 49 HGNC:10593 HGNC:10597 Acyl sulfonamide NaV1.7 inhibitors Bristol-Myers Squibb Company 11/07/202D 3D TSV
US10550073 35 25 HGNC:2623 HGNC:6876 Benzamide derivative CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. 11/07/202D 3D TSV
US10550089 124 62 HGNC:3538 Inhibitors of protease-activated receptor-2 Heptares Therapeutics Limited 11/07/202D 3D TSV
US10544132 133 130 HGNC:6973 Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity ASTEX THERAPEUTICS LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED 11/07/202D 3D TSV
US10548897 8 8 KSR antagonists Icahn School of Medicine at Mount Sinai 11/07/202D 3D TSV
US10544136 207 163 HGNC:3167 HGNC:3165 Modulators of sphingosine phosphate receptors The Scripps Research Institute 11/07/202D 3D TSV
US10550099 297 182 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors Forma Therapeutics, Inc. 11/07/202D 3D TSV
US10548896 122 119 HGNC:29079 Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas Celgene Quanticel Research, Inc. 11/07/202D 3D TSV
US10544143 3210 878 HGNC:15633 HGNC:15631 HGNC:15632 4-azaindole compounds Bristol-Myers Squibb Company 11/02/202D 3D TSV
US10544152 10 9 HGNC:5295 5-HT2CR agonist analogs The Board of Regents of The University of Texas System; University of Houston System 11/02/202D 3D TSV
US10544146 4 1 Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors FEDORA PHARMACEUTICALS INC. 11/02/202D 3D TSV
US10544151 11 11 HGNC:6307 Compounds and uses thereof Kala Pharmaceuticals, Inc. 11/02/202D 3D TSV
US10544141 90 76 Derivatives and methods of treating hepatitis B infections NOVIRA THERAPEUTICS, INC. 11/02/202D 3D TSV
US10544133 168 150 HGNC:17967 Heteroaryl substituted pyridyl compounds useful as kinase modulators Bristol-Myers Squibb Company 11/02/202D 3D TSV
US10533001 238 213 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:11491 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. 11/02/202D 3D TSV
US10544128 732 235 HGNC:4617 HGNC:3091 Isoquinolin-3-yl carboxamides and preparation and use thereof Samumed, LLC 11/02/202D 3D TSV
US10544130 1497 489 Metallo-beta-lactamase inhibitors Merck Sharp & Dohme Corp. 11/02/202D 3D TSV
US10544147 185 117 HGNC:8977 Purine inhibitors of human phosphatidylinositol 3-kinase delta Merck Sharp & Dohme Corp. 11/02/202D 3D TSV
US10533010 416 376 HGNC:6943 HGNC:992 HGNC:990 Substituted indole Mcl-1 inhibitors Vanderbilt University 11/02/202D 3D TSV
US10544126 111 107 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED 11/02/202D 3D TSV
US10532048 12 12 HGNC:1113 Tetrahydroisoquinolin-1-one derivative or salt thereof Seldar Pharma Inc. 11/02/202D 3D TSV
US10544095 38 38 HGNC:11708 3-indol substituted derivatives, pharmaceutical compositions and methods for use Pfizer Inc.; iTeos Therapeutics 11/01/202D 3D TSV
US10544117 30 30 HGNC:5302 5-hydroxytryptamine receptor 7 activity modulators and their method of use Temple University—Of The Commonwealth System of Higher Education 11/01/202D 3D TSV
US10543221 20 13 Beta-lactamase inhibitors, formulations, and uses thereof University of South Florida; The Regents of the University of California 11/01/202D 3D TSV
US10544120 343 331 HGNC:19679 Biaryl kinase inhibitors Bristol-Myers Squibb Company 11/01/202D 3D TSV
US10544106 98 96 HGNC:1133 Certain chemical entities, compositions, and methods NEUPHARMA, INC. 11/01/202D 3D TSV
US10544104 437 141 HGNC:4840 HGNC:11283 HGNC:76 Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR CO 11/01/202D 3D TSV
US10543207 74 73 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders ARDELYX, INC. 11/01/202D 3D TSV
US10544075 8 4 HGNC:11799 HGNC:11796 Derivatives of sobetirome OREGON HEALTH & SCIENCE UNIVERSITY 11/01/202D 3D TSV
US10543198 75 75 HGNC:29079 Inhibitor of lysine specific demethylase-1 Celgene Quanticel Research, Inc. 11/01/202D 3D TSV
US10543199 18 5 HGNC:427 Macrocycle and composition comprising thereof Shenzhen TargetRx, Inc. 11/01/202D 3D TSV
US10543194 6 6 Organic compounds INTRA-CELLULAR THERAPIES, INC. 11/01/202D 3D TSV
US10544110 36 35 HGNC:644 Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer University of Pittsburgh—Of the Commonwealth System of Higher Education 11/01/202D 3D TSV
US10544113 206 201 HGNC:5302 Thiazolidinone compounds and use thereof National Health Research Institute; Regents of the University of Minnesota 11/01/202D 3D TSV
US10543183 12 6 HGNC:7966 HGNC:7965 Treatment and diagnosis of melanoma The Rockefeller University 11/01/202D 3D TSV
US10543213 122 118 HGNC:29079 Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas Celgene Quanticel Research, Inc. 11/01/202D 3D TSV
US10526325 98 57 HGNC:8810 Bicyclic heterocyclic derivatives Merck Patent GmbH 10/25/202D 3D TSV
US10526329 367 214 HGNC:3357 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV 10/25/202D 3D TSV
US10526336 212 98 HGNC:4849 HGNC:4848 Fused heteroaryl derivatives as orexin receptor antagonists Merck, Sharp & Dohme Corp. 10/25/202D 3D TSV
US10526330 112 16 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 JAK kinase inhibitor compounds for treatment of respiratory disease Theravance Biopharma R&D IP, LLC 10/25/202D 3D TSV
US10525036 90 58 HGNC:6877 HGNC:6871 Spirocyclic compounds Recurium IP Holdings, LLC 10/25/202D 3D TSV
US10513534 17 11 2′-chloro nucleoside analogs for HCV infection IDENIX PHARMACEUTICALS LLC; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE DE MONTPELLIER 10/24/202D 3D TSV
US10513522 84 41 HGNC:6190 HGNC:6192 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors Incyte Corporation; Incyte Holdings Corporation 10/24/202D 3D TSV
US10512634 132 40 HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity KANCERA AB 10/24/202D 3D TSV
US10513493 31 31 HGNC:29079 Cyclopropylamines as LSD1 inhibitors Incyte Corporation 10/24/202D 3D TSV
US10513512 7 7 HGNC:3023 Flavanone derivatives, and preparation method and use thereof Xuanwu Hospital of Capital Medical University 10/24/202D 3D TSV
US10513523 249 246 HGNC:4571 Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators Janssen Pharmaceutica NV 10/24/202D 3D TSV
US10513499 22 22 HGNC:19288 Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase TES Pharma S.r.l. 10/24/202D 3D TSV
US10513518 46 38 HGNC:6255 Inhibitors of the renal outer medullary potassium channel Merck Sharp & Dohme Corp. 10/24/202D 3D TSV
US10512644 125 47 HGNC:8153 HGNC:8154 HGNC:8156 Oligomer-opioid agonist conjugates Inheris Pharmaceuticals, Inc. 10/24/202D 3D TSV
US10513524 10 5 HGNC:8795 HGNC:8775 PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases H. LUNDBECK A/S 10/24/202D 3D TSV
US10513514 34 32 HGNC:20001 Piperidine compounds as PCSK9 inhibitors SHENZHEN SALUBRIS PHARM CO LTD. 10/24/202D 3D TSV
US10513507 13 11 HGNC:12630 Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors FORMA Therapeutics, Inc. 10/24/202D 3D TSV
US10513520 6 6 HGNC:4912 Sulfamide and sulfamate inhibitors of hHint1 Regents of the University of Minnesota 10/24/202D 3D TSV
US10519167 3 3 HGNC:10894 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies CTXT PTY LTD 10/19/202D 3D TSV
US10519153 34 11 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Fused imidazo-piperidine JAK inhibitors Theravance Biopharma R&D IP, LLC 10/19/202D 3D TSV
US10519177 802 696 Heterocyclic compounds and uses thereof Plexxikon Inc. 10/19/202D 3D TSV
US10519118 167 165 HGNC:29079 KDM1A inhibitors for the treatment of disease Imago Biosciences, Inc. 10/19/202D 3D TSV
US10517849 9 9 HGNC:29079 LSD1 inhibitors and medical uses thereof Constellation Pharmaceuticals, Inc. 10/19/202D 3D TSV
US10517872 30 15 HGNC:17967 Pyridazinone macrocycles as IRAK inhibitors and uses thereof Merck Patent GmbH 10/19/202D 3D TSV
US10519163 252 89 HGNC:7027 HGNC:12446 Pyrrolopyrimidine derivatives as TAM inhibitors Incyte Corporation 10/19/202D 3D TSV
US10517878 110 106 HGNC:6871 Serine/threonine kinase inhibitors GENENTECH, INC. 10/19/202D 3D TSV
US10517858 327 107 HGNC:19310 HGNC:8987 Thiazolecarboxamides and pyridinecarboxamide compounds useful as PIM kinase inhibitors Incyte Holdings Corporation; Incyte Corporation 10/19/202D 3D TSV
US10512632 603 190 HGNC:8775 HGNC:8774 HGNC:8776 1 H-pyrazolo[4,3-B]pyridines as PDE1 inhibitors H. Lundbeck A/S 10/18/202D 3D TSV
US10508119 51 49 HGNC:436 Pyrazole derivatives useful as 5-lipdxygenase activating protein (FLAP) inhibitors ASTRAZENECA AB 10/18/202D 3D TSV
US10508120 1366 1156 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. 10/18/202D 3D TSV
US10508115 134 73 HGNC:15631 HGNC:6018 Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor Bristol-Myers Squibb Company 10/18/202D 3D TSV
US10508104 531 514 HGNC:339 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1H)-one as APJ agonists Bristol-Myers Squibb Company 10/12/202D 3D TSV
US10501438 16 16 HGNC:13575 Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals Neomed Institute 10/12/202D 3D TSV
US10508103 138 51 HGNC:11892 Benzimidazole-linked indole compound acting as novel divalent IAP antagonist MEDSHINE DISCOVERY INC. 10/12/202D 3D TSV
US10508109 306 303 HGNC:17287 Bicyclic compound and use thereof for inhibiting SUV39H2 ONCOTHERAPY SCIENCE, INC. 10/12/202D 3D TSV
US10501436 207 36 HGNC:171 HGNC:1076 HGNC:172 HGNC:175 Compounds and methods of use Medivation Technologies LLC 10/12/202D 3D TSV
US10500194 30 30 Covalent small molecule DCN1 inhibitors and therapeutic methods using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN 10/12/202D 3D TSV
US10501473 12 12 Fused heterocyclic ring compounds and method of treating retinal disease using same THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC) 10/12/202D 3D TSV
US10501467 122 66 HGNC:270 HGNC:272 HGNC:15677 HGNC:273 Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors BEIGENE, LTD. 10/12/202D 3D TSV
US10501440 42 26 HGNC:6371 Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors Boehringer Ingelheim International GmbH 10/12/202D 3D TSV
US10508105 148 117 HGNC:4596 Indazole compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction Vanderbilt University 10/12/202D 3D TSV
US10508102 28 13 HGNC:11892 Inhibitors of cellular necrosis and related methods President and Fellows of Harvard College; Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences 10/12/202D 3D TSV
US10508099 951 303 HGNC:4617 HGNC:3091 Isoquinolin-3-yl carboxamides and preparation and use thereof Samumed, LLC 10/12/202D 3D TSV
US10501452 149 37 HGNC:3023 Lactam compound derivative and application thereof NHWA PHARMA. CORPORATION 10/12/202D 3D TSV
US10508107 58 20 HGNC:6251 HGNC:17734 HGNC:11049 Morpholine derivative Hoffmann-La Roche Inc. 10/12/202D 3D TSV
US10501451 28 15 Selective NR2B antagonists Bristol-Myers Squibb Company 10/12/202D 3D TSV
US10501411 555 283 Substituted benzamides Hoffmann-La Roche Inc. 10/12/202D 3D TSV
US10501458 72 37 HGNC:11708 HGNC:6059 Substituted bicyclic fused ring compounds as indoleamine-2,3-dioxygenase inhibitors Iomet Pharma Ltd.; Merck Sharp & Dohme Corp. 10/12/202D 3D TSV
US10501449 69 68 HGNC:6255 Substituted nitrogen containing compounds Bristol-Myers Squibb Company 10/12/202D 3D TSV
US10501435 18 5 HGNC:4177 Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity Northwestern University 10/12/202D 3D TSV
US10508108 131 121 Tricyclic compounds as inhibitors of mutant IDH enzymes Merck Sharp & Dohme Corp. 10/12/202D 3D TSV
US10501466 33 33 HGNC:12757 WDR5 inhibitors and modulators Vanderbilt University 10/12/202D 3D TSV
US10507215 42 14 HGNC:6833 HGNC:6834 HGNC:404 Compounds for the treatment of addiction Amygdala Neurosciences, Inc. 10/02/202D 3D TSV
US10508088 214 193 HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 Methods using HDAC11 inhibitors FORMA Therapeutics, Inc. 10/02/202D 3D TSV
US10494380 32 31 HGNC:2623 Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity Shionogi & Co., Ltd. 10/02/202D 3D TSV
US10508086 253 218 HGNC:8605 HGNC:270 PARG inhibitory compounds Cancer Research Technology Limited 10/02/202D 3D TSV
US10507209 33 11 HGNC:3432 HGNC:3430 HGNC:3236 Quinazoline derivatives substituted by aniline, preparation method and use thereof XUANZHU PHARMA CO, LTD. 10/02/202D 3D TSV
US10508098 13 13 HGNC:12630 Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors FORMA Therapeutics, Inc. 10/02/202D 3D TSV
US10493060 92 59 HGNC:6877 HGNC:6871 Spirocyclic compounds Recurium IP Holdings, LLC 10/02/202D 3D TSV
US10508083 266 256 HGNC:4849 Substituted piperidine compound and use thereof Takeda Pharmaceutical Company Limited 10/02/202D 3D TSV
US10494376 120 118 HGNC:10894 Tetrahydroisoquinoline derived PRMT5-inhibitors CTXT PTY. LTD. 10/02/202D 3D TSV
US10479795 816 404 HGNC:8978 HGNC:8977 Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors Incyte Corporation 09/26/202D 3D TSV
US10479803 38 29 HGNC:6190 HGNC:8977 Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors Incyte Corporation 09/25/202D 3D TSV
US9975885 182 31 Broad-spectrum non-covalent coronavirus protease inhibitors PURDUE RESEARCH FOUNDATION 09/25/202D 3D TSV
US10479788 156 155 HGNC:12401 Compounds that inhibit MPS1 kinase Cancer Research Technology Limited 09/25/202D 3D TSV
US10479794 202 66 HGNC:8772 Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide Boehringer Ingelheim International GmbH 09/25/202D 3D TSV
US10478426 8 7 Enhancer of Zeste Homolog 2 inhibitors GLAXOSMITHKLINE LLC 09/25/202D 3D TSV
US10479798 32 32 HGNC:3009 Six-membered ring benzo derivatives as DPP-4 inhibitor and use thereof EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY; SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES 09/25/202D 3D TSV
US10479784 603 576 HGNC:882 Substituted pyrazin-2-amines as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED 09/25/202D 3D TSV
US10478424 2922 955 HGNC:15633 [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds Bristol-Myers Squibb Company 09/24/202D 3D TSV
USRE47740 6 6 HGNC:6027 Aminopyridinecarboxamides as CXCR2 modulators Syntrix Biosystems Inc. 09/20/202D 3D TSV
US10487111 12 12 HGNC:10906 IBAT inhibitors for the treatment of liver diseases Albireo AB 09/20/202D 3D TSV
US10487086 77 77 HGNC:3529 Macrocycles as factor XIa inhibitors Bristol-Myers Squibb Company 09/20/202D 3D TSV
US10485800 204 202 HGNC:6850 Mixed lineage kinase inhibitors for HIV/AIDS therapies The University of Rochester; Board of Regents of the University of Nebraska 09/20/202D 3D TSV
US10487087 38 25 HGNC:4324 Positive allosteric modulators of the GLP-1 receptor Vanderbilt University 09/20/202D 3D TSV
US10487092 126 124 Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT 09/20/202D 3D TSV
US10485803 106 42 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Pyrimidine compounds as JAK kinase inhibitors THERAVANCE BIOPHARMA R&D IP, LLC 09/20/202D 3D TSV
US10487083 60 15 Small molecule inhibitors of the JAK family of kinases Janssen Pharmaceutica NV 09/20/202D 3D TSV
US10478423 74 37 HGNC:6342 HGNC:3765 Substituted indazole derivatives active as kinase inhibitiors NERVIANO MEDICAL SCIENCES S.R.L. 09/20/202D 3D TSV
US10487084 22 13 HGNC:15631 HGNC:6018 Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor Bristol-Myers Squibb Company 09/20/202D 3D TSV
US10472354 838 389 HGNC:8534 1,3-thiazol-2-yl substituted benzamides Bayer Aktiengesellschaft 09/14/202D 3D TSV
US10472358 196 86 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins Incyte Corporation 09/14/202D 3D TSV
US10472324 9 9 2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives ALGIAX PHARMACEUTICALS GMBH 09/14/202D 3D TSV
US10472364 86 80 HGNC:8021 Ectonucleotidase inhibitors and methods of use thereof Calithera Biosciences, Inc. 09/14/202D 3D TSV
US10472344 12 7 HGNC:3529 HGNC:6357 Factor XIa inhibitors Merck Sharp & Dohme Corp. 09/14/202D 3D TSV
US10472367 5 5 HGNC:7029 Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors INCYTE INCORPORATION; INCYTE HOLDINGS CORPORATION 09/14/202D 3D TSV
US10464947 570 277 HGNC:13575 Tricyclic heterocycles as BET protein inhibitors Incyte Holdings Corporation; Incyte Corporation 09/09/202D 3D TSV
US10464911 88 76 HGNC:4852 HGNC:14064 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same Chong Kun Dang Pharmaceutical Corp. 09/08/202D 3D TSV
US10464927 98 49 HGNC:1777 HGNC:1773 2,4-disubstituted pyrimidines as CDK inhibitors Shanghai Xunhe Pharmaceutical Technology Co. Ltd. 09/08/202D 3D TSV
US10464928 3 3 HGNC:550 Amino pyrimidine SSAO inhibitors Eli Lilly and Company 09/08/202D 3D TSV
US10463675 468 113 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Aminopyrimidinyl compounds Pfizer Inc. 09/08/202D 3D TSV
US10457703 240 234 HGNC:7967 Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof Enanta Pharmaceuticals, Inc. 09/08/202D 3D TSV
US10464907 29 29 Compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof INDUSTRY ACADEMIC COOPERATION FOUNDATION KEIMYUNG UNIVERSITY 09/08/202D 3D TSV
US10464902 10 10 HGNC:6307 Multi-tyrosine kinase inhibitors derivatives and methods of use Ontogenesis, LLC 09/08/202D 3D TSV
US10464918 11 11 HGNC:11331 Process of making somatostatin modulators CRINETICS PHARMACEUTICALS, INC. 09/08/202D 3D TSV
US10463663 68 66 HGNC:2671 Pyridazinone compounds and their use as DAAO inhibitors Takeda Pharmaceutical Company Limited 09/08/202D 3D TSV
US10464919 346 184 HGNC:270 HGNC:19297 HGNC:11940 Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same Je Il Pharmaceutical Co., Ltd. 09/08/202D 3D TSV
US10457637 170 120 HGNC:5981 Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (RORγ(T)) GALDERMA RESEARCH & DEVELOPMENT 09/07/202D 3D TSV
US10457678 10 10 HGNC:195 Substituted pyrrolo[2,3-b]pyridines as inhibitors of cellular necroptosis Institut National de la Sante et de la Recherche Medicale (INSERM); Centre National de la Recherche Scientifique (CNRS); Sorbonne Universite; Universite Claude Bernard Lyon 1 09/07/202D 3D TSV
US10457681 16 11 HGNC:15631 HGNC:6018 Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor Bristol_Myers Squibb Company 09/07/202D 3D TSV
US10457686 14 7 HGNC:2160 HGNC:2159 [1,2,3]triazolo[4,5-D]pyrimidine derivatives Hoffmann-La Roche Inc. 09/07/202D 3D TSV
US10457685 76 38 HGNC:2160 HGNC:2159 [1,2,3]triazolo[4,5-D]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor Hoffmann-La Roche Inc. 09/07/202D 3D TSV
US10457684 30 15 HGNC:2160 HGNC:2159 [1,2,3]triazolo[4,5-d]pyrimidine derivatives Hoffmann-La Roche Inc. 09/07/202D 3D TSV
US10450301 191 190 HGNC:6857 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Enanta Pharmaceuticals, Inc. 08/31/202D 3D TSV
US10450313 162 54 HGNC:3690 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR inhibitors Incyte Holdings Corporation 08/31/202D 3D TSV
US10450298 7 6 HGNC:3357 PET Imaging agents Novartis AG 08/31/202D 3D TSV
US10450297 341 328 Sulfonyl amide derivatives for the treatment of abnormal cell growth Pfizer, Inc. 08/31/202D 3D TSV
US10450321 14 7 HGNC:2160 HGNC:2159 [1,2,3]triazolo[4,5-D]pyrimidine derivatives Hoffmann-La Roche Inc. 08/31/202D 3D TSV
US10450296 510 168 HGNC:19310 HGNC:8987 Heterocyclic compounds useful as Pim kinase inhibitors Incyte Corporation 08/30/202D 3D TSV
US10457672 128 128 HGNC:15983 γ-diketones as Wnt/β-catenin signaling pathway activators Samumed, LLC 08/24/202D 3D TSV
US10323028 67 55 1,3,4-thiadiazole compounds and their use in treating cancer AstraZeneca AB 08/24/202D 3D TSV
US10442759 21 21 1-sulfonamido-4-aryloxy compounds, and preparation method and medicinal application thereof CHINA PHARMACEUTICAL UNIVERSITY 08/24/202D 3D TSV
US10457647 40 40 HGNC:1133 Amino pyrimidine derivatives Novartis AG 08/24/202D 3D TSV
US10323037 118 118 HGNC:1133 Aminopyridazinone compounds as protein kinase inhibitors JIANGSU HENGRUI MEDICINE CO., LTD. 08/24/202D 3D TSV
US10435408 19 19 HGNC:5302 Azepine derivatives as 5-HT7 receptor modulators Korea Institute of Science and Technology 08/24/202D 3D TSV
US10377755 15 15 HGNC:990 BCL-2 inhibitors Newave Pharmaceutical Inc. 08/24/202D 3D TSV
US10442772 248 182 Benzimidazol-2-amines as mIDH1 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT 08/24/202D 3D TSV
US10457669 927 912 HGNC:6871 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. 08/24/202D 3D TSV
US10307425 116 115 Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases University of Washington 08/24/202D 3D TSV
US10376513 368 348 HGNC:8977 Heterocyclylamines as PI3K inhibitors Incyte Holdings Corporation 08/24/202D 3D TSV
US10457675 96 86 HGNC:14065 Histone deacetylase inhibitors and compositions and methods of use thereof CHDI Foundation, Inc. 08/24/202D 3D TSV
US10329260 302 298 HGNC:6371 Human plasma kallikrein inhibitors BioCryst Pharmaceuticals, Inc. 08/24/202D 3D TSV
US10457677 471 137 HGNC:8979 HGNC:8978 HGNC:795 HGNC:3942 Imidazolonylquinolines and the use thereof as ATM kinase inhibitors Merck Patent GmbH 08/24/202D 3D TSV
US10323013 21 21 HGNC:3449 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 08/24/202D 3D TSV
US10441590 9 2 HGNC:5302 HGNC:5301 HGNC:3023 HGNC:5286 HGNC:5294 Methods for treating pulmonary hypertension Reviva Pharmaceuticals, Inc. 08/24/202D 3D TSV
US10399948 138 60 Negative allosteric modulators of metabotropic glutamate receptor 3 Vanderbilt University 08/24/202D 3D TSV
US10456385 31 31 HGNC:1960 Pharmaceutical composition comprising pyridone derivatives SK BIOPHARMACEUTICALS CO., LTD. 08/24/202D 3D TSV
US10399980 544 539 HGNC:12607 Purinones as ubiquitin-specific protease 1 inhibitors FORMA Therapeutics, Inc. 08/24/202D 3D TSV
US10442808 127 124 Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors Novartis AG 08/24/202D 3D TSV
US10329300 80 80 HGNC:3430 Pyrazolo[3,4-d]pyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. 08/24/202D 3D TSV
US10442810 438 145 HGNC:7027 HGNC:12446 Pyrrolotriazine compounds as TAM inhibitors Incyte Corporation 08/24/202D 3D TSV
US10301261 220 104 HGNC:10260 Substituted indoles as modulators of ROR-gamma Vitae Pharmaceuticals, LLC 08/24/202D 3D TSV
US10441581 2116 815 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array Biopharma Inc. 08/24/202D 3D TSV
US10456394 62 18 HGNC:4852 HGNC:14065 HGNC:14064 HGNC:19086 HGNC:14063 HGNC:14068 HGNC:14067 HGNC:13315 HGNC:4854 HGNC:4853 HGNC:18128 Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 08/24/202D 3D TSV
US10457654 393 239 HGNC:10597 Therapeutic compounds and methods of use thereof GENENTECH, INC. 08/24/202D 3D TSV
US10442819 556 509 Tricyclic compounds as inhibitors of mutant IDH enzymes Merck Sharp & Dohme Corp. 08/24/202D 3D TSV
US10442803 546 273 HGNC:13575 Tricyclic heterocycles as bet protein inhibitors Incyte Corporation 08/24/202D 3D TSV
US9951068 213 154 HGNC:6251 HGNC:550 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN LIMITED 08/19/202D 3D TSV
US10428066 213 155 HGNC:6251 HGNC:550 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC 08/19/202D 3D TSV
US10428044 491 480 HGNC:1148 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones Bayer Pharma Aktiengesellschaft 08/17/202D 3D TSV
US10428063 47 46 4H-pyrrolo[3,2-C]pyridin-4-one derivatives Bayer Pharma Aktiengesellschaft 08/17/202D 3D TSV
US10435406 8 5 HGNC:8154 HGNC:8156 6,7-cyclicmorphinan derivatives and use thereof Purdue Pharma L.P. 08/17/202D 3D TSV
US10428108 98 93 Difluoroketamide derivatives Hoffmann-La Roche Inc. 08/17/202D 3D TSV
US10428068 73 62 HGNC:5253 HGNC:1735 Fused amino pyridine as HSP90 inhibitors Curis, Inc. 08/17/202D 3D TSV
US10428028 43 15 HGNC:4852 HGNC:4854 HGNC:4853 HDAC inhibitors BIOMARIN PHARMACEUTICAL INC. 08/17/202D 3D TSV
US10428083 23 6 HGNC:268 HGNC:262 HGNC:263 HGNC:264 Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor BAYER PHARMA AKTIENGESELLSCHAFT 08/17/202D 3D TSV
US10426135 104 104 Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof Pfizer Inc. 08/17/202D 3D TSV
US10428024 85 52 HGNC:8810 Piperidinyl derivatives MERCK PATENT GMBH 08/17/202D 3D TSV
US10428087 125 82 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Pyrimidinones as PI3K inhibitors Incyte Corporation 08/17/202D 3D TSV
US10428074 130 69 HGNC:6190 HGNC:6192 HGNC:6193 Pyrrole heteroaryl ring derivative and method of use thereof Jiangsu Hengrui Medicine Co., Ltd. 08/17/202D 3D TSV
US10428076 247 231 Soluble guanylate cyclase stimulators Merck Sharp & Dohme Corp. 08/17/202D 3D TSV
US10428104 118 117 HGNC:10894 Substituted nucleoside derivatives useful as anticancer agents Pfizer Inc. 08/17/202D 3D TSV
USRE47636 27 27 HGNC:2528 Substituted spirocycles Boehringer Ingelheim International GmbH 08/17/202D 3D TSV
US10435415 152 43 HGNC:6192 HGNC:1133 Substituted tetrahydrocarbazole and carbazole carboxamide compounds Bristol-Myers Squibb Company 08/17/202D 3D TSV
US10435407 170 169 HGNC:2730 Triaza-spirodecanones as DDR1 inhibitors Hoffmann-La Roche Inc. 08/17/202D 3D TSV
US10435414 215 214 HGNC:8979 Tricyclic PI3K inhibitor compounds and methods of use Genentech, Inc. 08/17/202D 3D TSV
US10435400 122 57 HGNC:3236 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO. LTD. 08/16/202D 3D TSV
US10435396 47 47 HGNC:17967 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs Bayer Pharma Aktiegesellschaft 08/16/202D 3D TSV
US10435392 28 13 Bipyrazole derivatives as JAK inhibitors Incyte Corporation 08/16/202D 3D TSV
US10434101 94 47 HGNC:3236 Heterocyclic compounds and uses thereof Celgene CAR LLC 08/16/202D 3D TSV
US10435355 26 13 HGNC:3553 Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments The Regents of the University of California 08/16/202D 3D TSV
US10435361 318 118 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 Kinase inhibitors Topivert Pharma Limited 08/16/202D 3D TSV
US10434085 15 14 HGNC:6859 Non-aromatic difluoro analogues of resorcylic acid lactones University of North Carolina at Greensboro 08/16/202D 3D TSV
US10435398 70 33 HGNC:4849 HGNC:4848 Oxazole orexin receptor antagonists Merck Sharp & Dohme Corp. 08/16/202D 3D TSV
US10435405 241 235 HGNC:6863 Pyrazolopyridine compounds and uses thereof Incyte Corporation 08/16/202D 3D TSV
US10435369 304 268 Tricyclic sulfones as ROR gamma modulators Bristol-Myers Squibb Company 08/16/202D 3D TSV
US10434112 188 179 HGNC:3827 Use of agonists of formyl peptide receptor 2 for treating dermatological diseases ALLERGAN, INC. 08/16/202D 3D TSV
US10435379 9 9 HGNC:6018 [4-(1,3,3-trimethyl-2-OXO-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof SANTEN PHARMACEUTICAL CO., LTD. 08/16/202D 3D TSV
US10421756 152 74 HGNC:4852 HGNC:4853 Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase Rodin Therapeutics, Inc. 08/12/202D 3D TSV
US10421760 61 20 HGNC:6190 HGNC:6192 HGNC:6193 Pyrrolo[2,3-d]pyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. 08/12/202D 3D TSV
US10420768 72 22 HGNC:4586 HGNC:6251 HGNC:2625 Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists Rugen Holdings (Cayman) Limited 08/12/202D 3D TSV
US10421747 35 7 HGNC:6307 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Quinoxaline derivatives useful as FGFR kinase modulators ASTEX THERAPEUTICS LTD 08/12/202D 3D TSV
US10421750 47 47 HGNC:8157 Substituted morpholine derivatives having activity against pain ESTEVE PHARMACEUTICALS, S.A. 08/12/202D 3D TSV
US10421742 516 252 HGNC:6371 HGNC:3529 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT 08/12/202D 3D TSV
US10421722 9 9 HGNC:10936 Sulfur-containing compounds targeting vesicular acetylcholine transporter Washington University 08/12/202D 3D TSV
US10421743 3 3 HGNC:10894 Tetrahydroisoquinolines as PRMT5 inhibitors CTXT PTY LTD 08/12/202D 3D TSV
US10421765 101 99 Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase Board of Regents, The University of Texas System 08/12/202D 3D TSV
US10414734 32 27 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT 08/02/202D 3D TSV
US10413562 298 295 HGNC:1133 Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity Merck Patent GmbH 08/02/202D 3D TSV
US10414761 375 111 HGNC:6833 HGNC:6834 HGNC:29079 Cyclopropanamine compound and use thereof Takeda Pharmaceutical Company Limited 08/02/202D 3D TSV
US10414797 100 23 HGNC:7173 HGNC:7174 HGNC:7176 HGNC:7155 Gelatinase inhibitors and use thereof Iproteos S.L 08/02/202D 3D TSV
US10413545 98 97 HGNC:3594 Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer Janssen Pharmaceutica NV 08/02/202D 3D TSV
US10413550 137 136 Isoxazole compounds as inhibitors of heat shock proteins The Institute of Cancer Research 08/02/202D 3D TSV
US10414731 16 16 HGNC:3529 Substituted oxopyridine derivatives BAYER PHARMA AKTIENGESELLSCHAFT 08/02/202D 3D TSV
US10414765 104 48 HGNC:6283 HGNC:6278 Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same BAYER PHARMA AKTIENGESELLSCHAFT 08/02/202D 3D TSV
US10399985 41 41 HGNC:8772 (Hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders Hoffmann-La Roche Inc. 07/27/202D 3D TSV
US10407409 426 417 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD Takeda Pharmaceutical Company Limited 07/27/202D 3D TSV
US10407446 78 13 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:11393 HGNC:11390 HGNC:12401 Amino-triazolopyridine compounds and their use in treating cancer AstraZeneca AB 07/27/202D 3D TSV
US10406136 18 9 Composition for suppressing neuraminidase activity comprising geranylated flavonoid derived from Paulownia tomentosa as active ingredient INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY 07/27/202D 3D TSV
US10407441 14 7 Compositions and methods for treating neoplasia, inflammatory disease and other disorders Dana-Farber Cancer Institute, Inc. 07/27/202D 3D TSV
US10399973 27 27 HGNC:550 Compounds I BENEVOLENTAI CAMBRIDGE LIMITED 07/27/202D 3D TSV
US10407431 34 34 HGNC:15631 Compounds and compositions as toll-like receptor 7 agonists Novartis AG 07/27/202D 3D TSV
US10407423 40 23 HGNC:2976 HGNC:14129 Compounds as inhibitors of DNA methyltransferases FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA 07/27/202D 3D TSV
US10399967 143 139 HGNC:6001 Compounds for inflammation and immune-related uses PRCL RESEARCH INC. 07/27/202D 3D TSV
US10399976 220 153 Dihydropyrrolopyridine inhibitors of ROR-gamma Vitae Pharmaceuticals, LLC 07/27/202D 3D TSV
US10398702 108 27 Dimeric compounds Hoffmann-La Roche Inc. 07/27/202D 3D TSV
US10399961 15 15 HGNC:6371 Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors Boehringer Ingelheim International GmbH 07/27/202D 3D TSV
US10398706 9 7 Heteroaryldiazepine derivatives as RSV inhibitors Enanta Pharmaceuticals, Inc. 07/27/202D 3D TSV
US10399979 92 23 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Janus kinase inhibitors and uses thereof Purdue Research Foundation 07/27/202D 3D TSV
US10399991 64 64 HGNC:6221 Kv1.3 inhibitors and their medical applications 4SC AG 07/27/202D 3D TSV
US10399974 57 57 HGNC:12401 N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors Cancer Research Technology Limited 07/27/202D 3D TSV
US10399958 21 21 HGNC:9235 PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof Mitobridge, Inc. 07/27/202D 3D TSV
US10399989 279 96 HGNC:1133 HGNC:3236 Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer Loxo Oncology, Inc. 07/27/202D 3D TSV
US10407433 124 111 HGNC:9922 Substituted 4-phenylpiperidines, their preparation and use The Trustees of Columbia University In The City of New York 07/27/202D 3D TSV
US10399987 98 49 HGNC:11773 TGF beta receptor antagonists Bristol-Myer Squibb Company 07/27/202D 3D TSV
US10399939 40 40 HGNC:3467 Tetrahydronaphthalene estrogen receptor modulators and uses thereof Genentech, Inc. 07/27/202D 3D TSV
US10399945 74 68 HGNC:8031 Tetrahydronaphthyl urea derivative MOCHIDA PHARMACEUTICAL CO., LTD. 07/27/202D 3D TSV
US10406157 4 2 HGNC:4515 Tetrahydropyridopyrazine modulators of GPR6 Takeda Pharmaceutical Company Limited 07/27/202D 3D TSV
US10398703 23 23 HGNC:6307 Therapeutic compounds and uses thereof Kala Pharmaceuticals, Inc. 07/27/202D 3D TSV
US10407422 9 9 HGNC:7218 Triazolopyridine inhibitors of myeloperoxidase Bristol-Myers Squibb Company 07/27/202D 3D TSV
US10399972 70 66 Tricyclic compounds as inhibitors of mutant IDH enzymes Merck Sharp & Dohme Corp. 07/27/202D 3D TSV
US10392391 570 547 HGNC:882 Compounds useful as inhibitors of ATR kinase Vertex Pharmaceuticals Incorporated 07/20/202D 3D TSV
US10392402 22 11 HGNC:10251 HGNC:10252 Heterocyclic compounds as kinase inhibitors Translational Drug Development, LLC 07/20/202D 3D TSV
US10392376 131 119 Heterocyclic inhibitors of ATR kinase Board of Regents, The University of Texas System 07/20/202D 3D TSV
US10392346 187 72 HGNC:11491 HGNC:11283 HGNC:4616 Kinase inhibitors Topivert Pharma Limited 07/20/202D 3D TSV
US10392405 25 25 HGNC:17635 Macrocyclic immunomodulators ChemoCentryx, Inc. 07/20/202D 3D TSV
US10391089 334 330 HGNC:29652 PRMT5 inhibitors and uses therof Epizyme, Inc. 07/20/202D 3D TSV
US10392392 120 103 HGNC:6251 Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors Tolero Pharmaceuticals, Inc. 07/20/202D 3D TSV
US10385022 323 323 HGNC:19680 3-amino-pyridines as GPBAR1 agonists HOFFMANN-LA ROCHE INC. 07/13/202D 3D TSV
US10383871 19 19 HGNC:3553 Azetidine derivatives Vernalis (R&D) Ltd. 07/13/202D 3D TSV
US10383880 247 237 HGNC:8846 Carbazole-containing sulfonamides as cryptochrome modulators Synchronicity 07/13/202D 3D TSV
US10385066 36 35 HGNC:2843 Compounds as diacylglycerol acyltransferase inhibitors GlaxoSmithKline LLC 07/13/202D 3D TSV
US10383850 23 23 Indazole and indole derivatives as inhibitors of retinoic acid related orphan receptor gamma (ROR gamma) for the treatment of immune-related diseases ORCA PHARMACEUTICALS LIMITED 07/13/202D 3D TSV
US10377772 63 63 HGNC:18618 Macrocyclic LRRK2 kinase inhibitors Oncodesign S.A. 07/13/202D 3D TSV
US10377763 48 23 HGNC:4849 HGNC:4848 Morphinan derivative and medical usage thereof UNIVERSITY OF TSUKUBA 07/13/202D 3D TSV
US10385031 171 56 HGNC:4852 HGNC:4854 HGNC:4853 Substituted piperazines as selective HDAC1,2 inhibitors REGENACY PHARMACEUTICALS, LLC 07/13/202D 3D TSV
US10385036 35 35 Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof Pfizer Inc. 07/13/202D 3D TSV
US10377768 112 91 Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease Lycera Corporation 07/13/202D 3D TSV
US10383835 72 25 HGNC:3401 Treatment of inflammatory disorders in non-human mammals THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 07/13/202D 3D TSV
US10385052 28 7 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Tricyclic compound and JAK inhibitor Nissan Chemical Corporation 07/13/202D 3D TSV
US10377770 457 419 Tricyclic compounds and compositions as kinase inhibitors Novartis AG 07/13/202D 3D TSV
US10377742 493 490 HGNC:9377 AMPK-activating heterocyclic compounds and methods for using the same Rigel Pharmaceuticals, Inc. 07/06/202D 3D TSV
US10370370 89 58 HGNC:5297 HGNC:1960 Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors Axovant Sciences GmbH 07/06/202D 3D TSV
US10370368 11 9 HGNC:6713 Aryl acylsulfonamides as BLT1 antagonists Merck Sharp & Dohme Corp. 07/06/202D 3D TSV
US10370338 50 25 HGNC:15631 HGNC:15632 Benzazepine dicarboxamide compounds with tertiary amide function Hoffmann-La Roche Inc. 07/06/202D 3D TSV
US10377729 5 5 HGNC:12405 Bis-furan derivatives as transthyretin (TTR) stabilizers and amyloid inhibitors for the treatment of familial amyloid polyneuropathy (FAP) BSIM Therapeutics, S.A. 07/06/202D 3D TSV
US10370379 25 25 HGNC:8031 Compounds and compositions useful for treating disorders related to NTRK BLUEPRINT MEDICINES CORPORATION 07/06/202D 3D TSV
US10370352 7 7 HGNC:6857 Cyclobutyl-imidazolidinone compounds ELI LILLY AND COMPANY 07/06/202D 3D TSV
US10377717 104 104 HGNC:7967 Farnesoid X receptor agonists and uses thereof METACRINE, INC. 07/06/202D 3D TSV
US10370388 85 82 HGNC:338 Heterocyclic compounds and methods of their use NOVARTIS AG 07/06/202D 3D TSV
US10370375 84 28 Heterocyclyl-substituted cyclohexylsulfonamides as JAK inhibitors Elanco Tiergesundheit AG 07/06/202D 3D TSV
US10377746 20 20 Indolin-2-one derivatives Hoffmann-La Roche Inc. 07/06/202D 3D TSV
US10370339 48 47 N-Methylbenzimidazoles as mIDH1 inhibitors BAYER PHARMA AKTIENGESELLSCHAFT 07/06/202D 3D TSV
US10370337 5 5 Oxy-cyanoquinolinone PDE9 inhibitors Merck, Sharp & Dohme Corp. 07/06/202D 3D TSV
US10370336 6 5 Phenyl-cyanoquinolinone PDE9 inhibitors Merck Sharp & Dohme Corp. 07/06/202D 3D TSV
US10377744 62 55 HGNC:3402 Potent soluble epdxide hydrolase inhibitors Eicosis, LLC 07/06/202D 3D TSV
US10369153 249 142 HGNC:6190 HGNC:6192 HGNC:6193 Pyrrolopyrimidine compounds and uses thereof HUTCHISON MEDIPHARMA LIMITED 07/06/202D 3D TSV
US10370360 160 40 HGNC:6342 HGNC:2730 HGNC:2731 Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof The Board of Regents of the University of Texas System 07/06/202D 3D TSV
US10377753 634 628 HGNC:4586 Substituted 4-azaindoles and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV 07/06/202D 3D TSV
US10376531 17 17 HGNC:742 Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR Pfizer Inc. 07/06/202D 3D TSV
US10370333 169 163 HGNC:438 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 07/06/202D 3D TSV
US10370387 196 96 Tricyclic fused thiophene derivatives as JAK inhibitors Incyte Holdings Corporation 07/06/202D 3D TSV
US10376502 20 20 Alkylated imino sugars exhibiting glucosidase inhibition and their method of use TBA 06/29/202D 3D TSV
US10364255 43 41 Heteroaromatic compounds as Vanin inhibitors Boehringer Ingleheim International GmbH 06/29/202D 3D TSV
US10364242 3 1 HGNC:3553 HGNC:736 HGNC:735 Modulation of N-acylethanolamine-hydrolysing acid amidase (NAAA) for disease treatment Fondazione Istituto Italiano di Tecnologia 06/29/202D 3D TSV
US10364238 188 92 HGNC:6371 HGNC:6357 N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors Kalvista Pharmaceuticals Limited 06/29/202D 3D TSV
US10364234 5 2 HGNC:6251 HGNC:6255 Pyridinecarboxamide derivatives, preparation method thereof and pharmaceutical uses thereof Jiangsu Hengrui Medicine Co., Ltd. 06/29/202D 3D TSV
US10376504 6 6 Substituted quinolinones as PDE9 inhibitors Merck Sharp & Dohme Corp 06/29/202D 3D TSV
US10376514 304 300 HGNC:8775 Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6H)-ones Dart NeuroScience (Cayman) Ltd 06/29/202D 3D TSV
US10336729 95 95 HGNC:550 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors Boehringer Ingelheim International GmbH 06/21/202D 3D TSV
US10336739 253 250 HGNC:339 4-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonists Bristol-Myers Squibb Co. 06/21/202D 3D TSV
US10357546 20 10 HGNC:7175 HGNC:7176 Acceleration of diabetic wound healing University of Notre Dame du Lac 06/21/202D 3D TSV
US10336733 50 46 HGNC:6713 Aryl acylsulfonamides as BLT1 antagonists Merk Sharp & Dohme Corp. 06/21/202D 3D TSV
US10358446 67 16 HGNC:6735 HGNC:1057 HGNC:1133 HGNC:6524 Bruton's tyrosine kinase inhibitors ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO., LTD. 06/21/202D 3D TSV
US10336724 38 19 HGNC:2671 D-amino acid oxidase inhibitors and therapeutic uses thereof SyneuRx International (Taiwan) Corp. 06/21/202D 3D TSV
US10336755 23 23 HGNC:1133 Fused pyrazole derivatives, preparation method thereof, and use thereof in treatment of cancers, inflammation and immune diseases Beijing Innocare Pharma Tech Co., Ltd. 06/21/202D 3D TSV
US10336775 181 174 HGNC:7056 Glycosidase inhibitors Asceneuron SA 06/21/202D 3D TSV
US10358451 19 13 HGNC:11708 HGNC:6059 Heterocycles useful as IDO and TDO inhibitors Hangzhou Innogate Pharma Co., Ltd. 06/21/202D 3D TSV
US10336727 237 79 HGNC:9886 HGNC:17071 HGNC:18039 Histone demethylase inhibitors Celgene Quanticel Research Inc 06/21/202D 3D TSV
US10336734 12 3 HGNC:6192 HGNC:19297 HGNC:11283 HGNC:427 Inhibitors of ACK1/TNK2 tyrosine kinase H. Lee Moffitt Cancer Center and Research Institute Inc 06/21/202D 3D TSV
US10358436 643 201 HGNC:11393 HGNC:11390 HGNC:3765 Kinase inhibitors and method of treating cancer University Health Network 06/21/202D 3D TSV
US10357493 402 201 HGNC:4852 HGNC:14064 Metalloenzyme inhibitor compounds Selenity Therapeutics (Bermuda), Ltd. 06/21/202D 3D TSV
US10336774 68 64 HGNC:9644 N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 Novartis AG 06/21/202D 3D TSV
US10336754 22 8 HGNC:6371 HGNC:3529 Pyrimidinones as factor XIa inhibitors Bristol-Myers Squibb Co. 06/21/202D 3D TSV
US10336762 1932 935 HGNC:11892 HGNC:17967 Pyrrolo[1,2-b]pyridazine derivatives Gilead Sciences Inc 06/21/202D 3D TSV
US10336759 26 26 HGNC:6190 Salts and processes of preparing a PI3K inhibitor Incyte Corporation 06/21/202D 3D TSV
US10336731 14 14 HGNC:6059 Substituted 1H-indole-2-carboxamide compounds as indoleamine-2,3-dioxygenase inhibitors Merck Sharp & Dohme Corp 06/21/202D 3D TSV
US10358416 288 286 HGNC:4501 Substituted pyrrolidines as G-protein coupled receptor 43 agonists Epics Therapeutics 06/21/202D 3D TSV
US10336741 56 18 HGNC:3528 HGNC:3529 HGNC:3535 Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases Ono Pharmaceutical Co., Ltd 06/21/202D 3D TSV
US10336761 682 341 HGNC:11773 TGFβ receptor antagonist Bristol-Myers Squibb Co. 06/21/202D 3D TSV
US10336752 15 11 HGNC:12440 TYK2 inhibitors, uses, and methods for production thereof Nimbus Lakshmi, Inc. 06/21/202D 3D TSV
US10336757 25 25 HGNC:1735 Treatment of neurodegenerative diseases through inhibition of HSP90 Sloan-Kettering Institute for Cancer Research 06/21/202D 3D TSV
US10358435 116 66 Triazolyl pyrimidinone compounds as PDE2 inhibitors Merck Sharp & Dohme Corp 06/21/202D 3D TSV
US10358449 5 5 HGNC:3009 Xanthine derivative Jiangsu Tasly Diyi Pharmaceutical Co, LTD. 06/21/202D 3D TSV
US10351548 11 11 HGNC:8816 2-oxo-1,2-dihydropyridine-3-carboxamide compounds and their use as inhibitors of PDK1 International Society for Drug Development S.R.L. 06/12/202D 3D TSV
US10351563 236 233 HGNC:19679 Biaryl kinase inhibitors Bristol-Myers Squibb Co. 06/12/202D 3D TSV
US10351575 161 158 HGNC:8031 Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain Array BioPharma Inc 06/12/202D 3D TSV
US10351570 11 10 HGNC:6307 Compounds and uses thereof Kala Pharmaceuticals, Inc. 06/12/202D 3D TSV
US10351558 215 212 HGNC:3551 Factor IXa inhibitors Merck Sharp & Dohme Corp 06/12/202D 3D TSV
US10351547 267 263 HGNC:11331 Somatostatin modulators and uses thereof CRINETICS PHARMACEUTICALS, INC. 06/12/202D 3D TSV
US10343992 273 268 1-cyano-pyrrolidine compounds as USP30 inhibitors Missions Therapeutics Limited 06/09/202D 3D TSV
USRE47493 273 267 HGNC:3309 Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 06/09/202D 3D TSV
US10344000 39 35 Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp 06/09/202D 3D TSV
US10344025 605 595 GLS1 inhibitors for treating disease The University of Texas System 06/08/202D 3D TSV
US10344004 1 1 Inhibitor of the mutated isocitrate dehydrogenase IDH1 R132H Bayer Pharma Aktiengesellschaft 06/08/202D 3D TSV
US10344034 19 13 HGNC:4421 Pyrazolopyrimidone or Pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereof Shanghai Hengrui Pharmaceutical Co., Ltd 06/08/202D 3D TSV
US10342794 7 7 HGNC:11491 Substituted imidazo[1,2-a]pyrazines as Syk inhibitors Gilead Sciences Inc 06/08/202D 3D TSV
US10016430 30 15 HGNC:7218 HGNC:12015 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase AstraZeneca AB 06/01/202D 3D TSV
USRE46942 106 38 HGNC:270 HGNC:11941 HGNC:272 HGNC:15677 4-piperidinyl compounds for use as tankyrase inhibitors Novartis AG 06/01/202D 3D TSV
US10017516 326 67 HGNC:171 HGNC:1076 HGNC:172 HGNC:175 BMP inhibitors and methods of use thereof The Brigham and Women's Hospital, Inc. 06/01/202D 3D TSV
US10017501 84 42 Benzimidazole derivatives as bromodomain inhibitors Gilead Sciences Inc 06/01/202D 3D TSV
US10017502 22 18 Benzoxazinone amides as mineralocorticoid receptor modulators AstraZeneca AB 06/01/202D 3D TSV
US10016438 200 37 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 06/01/202D 3D TSV
US10016439 11 11 HGNC:4079 Fused imidazole compounds Ono Pharmaceutical Co., Ltd 06/01/202D 3D TSV
US10017504 140 68 HGNC:4849 HGNC:4848 Piperidine isoxazole and isothiazole orexin receptor antagonists Merck Sharp & Dohme Corp 06/01/202D 3D TSV
US10016420 14 14 HGNC:3357 Substituted pyridazines for the treatment of pain Inhibitaxin Limited 06/01/202D 3D TSV
US10017468 277 276 HGNC:4501 Substituted pyrrolidines as G-protein coupled receptor 43 agonists Ogeda SA 06/01/202D 3D TSV
US10336710 12 12 HGNC:17989 Benzimidazole derivatives, preparation method therefor, and applications thereof TBA 05/31/202D 3D TSV
US10336721 35 35 HGNC:7097 Biaryltriazole inhibitors of macrophage migration inhibitory factor Yale University 05/31/202D 3D TSV
US10329302 370 361 HGNC:17967 Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc 05/31/202D 3D TSV
US10329291 53 27 HGNC:934 HGNC:933 C5-C6-carbocyclic fused iminothiadiazine dioxides as BACE inhibitors, compositions, and their use TBA 05/31/202D 3D TSV
US10335399 59 59 HGNC:4594 Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2—negative allosteric modulators, compositions, and their use TBA 05/31/202D 3D TSV
US10335392 43 41 HGNC:11892 Cyclic compounds useful as modulators of TNF α Bristol-Myers Squibb Co. 05/31/202D 3D TSV
US10329286 11 11 FXR (NR1H4) modulating compounds Gilead Sciences Inc 05/31/202D 3D TSV
US10329299 436 107 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Heterocyclic compounds and uses thereof Infinity Pharmaceuticals Inc 05/31/202D 3D TSV
US10329307 74 70 Heterocyclic compounds as inhibitors of platelet aggregation Universite de Montreal 05/31/202D 3D TSV
US10329303 52 52 HGNC:23357 Heterocyclic inhibitors of monocarboxylate transporter The Scripps Research Institute 05/31/202D 3D TSV
US10336717 549 510 HGNC:933 Inhibitors of beta-secretase Vitae Pharmaceuticals, LLC 05/31/202D 3D TSV
US10335409 178 86 Inhibitors of hepatitis C virus Gilead Pharmasset LLC 05/31/202D 3D TSV
US10329320 66 61 Neuroactive steroids, compositions, and uses thereof Sage Therapeutics, Inc. 05/31/202D 3D TSV
US10335401 95 94 HGNC:7045 Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity Shionogi & Co., Ltd 05/31/202D 3D TSV
US10336684 60 53 HGNC:19061 Phenyl-(aza)cycloalkyl carboxylic acid GPR120 modulators Bristol=Myers Squibb Company 05/31/202D 3D TSV
US10329294 290 280 HGNC:17967 Pyrazolopyrimidine inhibitors of IRAK4 activity Merck Sharp & Dohme Corp 05/31/202D 3D TSV
US10329295 163 162 HGNC:17967 Pyrrolotriazine inhibitors of IRAK4 activity Merck Sharp & Dohme Corp 05/31/202D 3D TSV
US10329282 123 123 Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof Beijing Tide Pharmaceutical Co., Ltd 05/31/202D 3D TSV
US10335402 23 23 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders Takeda Pharmaceutical Co., Ltd 05/31/202D 3D TSV
USRE47451 45 9 HGNC:2730 HGNC:2731 Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases Hanmi Pharm. Co., Ltd 05/31/202D 3D TSV
US10011588 308 149 HGNC:4849 HGNC:4848 1,2-substituted cyclopentanes as orexin receptor antagonists Takeda Pharmaceutical Co., Ltd 05/26/202D 3D TSV
US10011627 18 9 HGNC:11037 HGNC:11036 C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof YOUNGENE THERAPEUTICS CO., LTD 05/26/202D 3D TSV
US10011599 101 99 HGNC:6840 Compounds and compositions as inhibitors of MEK Novartis AG 05/26/202D 3D TSV
US10011568 40 21 HGNC:11526 HGNC:2637 Cyclohexyl pyridine derivative Kissei Pharmaceutical Co., Ltd 05/26/202D 3D TSV
US10011595 242 120 HGNC:4849 HGNC:4848 Ethyldiamine orexin receptor antagonists Merck Sharp & Dohme Corp 05/26/202D 3D TSV
US10011607 111 111 HGNC:4596 Ethynyl derivatives Hoffman-La Roche Inc 05/26/202D 3D TSV
US10011593 16 13 HGNC:6307 HGNC:8804 HGNC:9437 Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors Allergan Inc 05/26/202D 3D TSV
US10011611 44 4 HGNC:4852 HGNC:14064 HGNC:19086 HGNC:14068 HGNC:13315 HGNC:4853 HGNC:18128 Histone deacetylase inhibitors and methods for use thereof Reaction Biology Corp 05/26/202D 3D TSV
US10011604 60 60 HGNC:8031 Method of treatment using substituted imidazo[1,2b]pyridazine compounds Array BioPharma Inc 05/26/202D 3D TSV
US10010547 147 147 HGNC:1925 Pharmaceutical compounds Cascadian Therapeutics, Inc. 05/26/202D 3D TSV
US10011571 26 3 HGNC:6190 HGNC:3763 HGNC:6192 HGNC:1057 HGNC:6193 HGNC:6171 HGNC:11584 HGNC:12440 HGNC:3767 Preparation method for aromatic heterocyclic compound used as selective JAK3 and/or JAK1 kinase inhibitor and application of aromatic heterocyclic compound SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. 05/26/202D 3D TSV
US10010539 216 108 HGNC:4848 Pyrazole, triazole and tetrazole orexin receptor antagonists Merck Sharp & Dohme Corp 05/26/202D 3D TSV
US10005769 79 78 HGNC:3092 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors 4SC AG 05/18/202D 3D TSV
US10005792 140 135 HGNC:10894 Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors CTXT PTY. LTD. 05/18/202D 3D TSV
US10005788 52 24 HGNC:7027 HGNC:12446 Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation 05/18/202D 3D TSV
US10005768 136 135 HGNC:10597 Carboxamide derivatives and use thereof Purdue Pharma LP 05/18/202D 3D TSV
US10004738 49 48 HGNC:933 Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines H. Lundbeck A/S 05/18/202D 3D TSV
US10005735 104 40 HGNC:2240 HGNC:16889 Inhibitors of RPN11 California Institute of Technology 05/18/202D 3D TSV
US10005783 105 105 HGNC:8031 Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Array BioPharma Inc 05/18/202D 3D TSV
US10005762 159 80 HGNC:6656 Pyridine derivatives Astellas Pharma Inc 05/18/202D 3D TSV
US10005756 77 76 HGNC:16672 Pyrrolidinone derivatives as MetAP-2 inhibitors Merck Patent GmbH 05/18/202D 3D TSV
US10005739 214 213 HGNC:2730 Quinazolinone and isoquinolinone derivative Chugai Seiyaku Kabushiki Kaisha 05/18/202D 3D TSV
US10005782 218 200 HGNC:1133 Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators BeiGene, Ltd 05/18/202D 3D TSV
US10004755 149 40 HGNC:7027 HGNC:12446 HGNC:3765 Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity University of North Carolina at Chapel Hill 05/18/202D 3D TSV
US10329256 159 43 HGNC:6833 HGNC:6834 HGNC:29079 (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors Oryzon Genomics, S.A. 05/11/202D 3D TSV
US10323042 246 64 HGNC:8781 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds Pfizer Inc 05/11/202D 3D TSV
US10323060 37 34 HGNC:7967 Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof Enanta Pharmaceuticals Inc 05/11/202D 3D TSV
US10000483 117 27 HGNC:1079 HGNC:1057 HGNC:1133 HGNC:6193 HGNC:11719 HGNC:7972 HGNC:3942 Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof Dana-Farber Cancer Institute Inc 05/11/202D 3D TSV
US9999624 8 8 HGNC:933 Combination Alzheimer therapy using anti-N3pGlu Abeta antibodies + a BACE inhibitor Eli Lilly and Company 05/11/202D 3D TSV
US10000507 426 142 HGNC:19310 HGNC:8987 Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors Incyte Corporation 05/11/202D 3D TSV
US10000487 21 13 HGNC:7110 HGNC:7111 Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers eFFECTOR Therapeutics Inc 05/11/202D 3D TSV
US10323032 332 111 HGNC:8537 P2X7 Modulators Janssen Pharmaceutica NV 05/11/202D 3D TSV
US9999619 794 387 Piperidin-4-yl azetidine derivatives as JAK1 inhibitors Incyte Holdings Corporation 05/11/202D 3D TSV
USRE47437 55 24 HGNC:1232 HGNC:12680 HGNC:14661 Prolyl hydroxylase inhibitors and methods of use Akebia Therapeutics, Inc. 05/11/202D 3D TSV
US10000468 22 21 HGNC:4515 Pyrazines as modulators of GPR6 Takeda Pharmaceutical Co., Ltd 05/11/202D 3D TSV
US10323038 290 143 Pyrazole compounds and methods of making and using same ABIDE THERAPEUTICS, INC. 05/11/202D 3D TSV
US10000476 229 150 HGNC:7160 HGNC:195 HGNC:7173 HGNC:7163 HGNC:7175 HGNC:7176 HGNC:7155 HGNC:7166 HGNC:7159 Pyridone derivative, pharmaceutical containing the same and methods of use thereof Kaken Pharmaceutical Co., Ltd 05/11/202D 3D TSV
US10328074 61 61 Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors Boehringer Ingelheim International GmbH 05/11/202D 3D TSV
US10328054 69 69 Substituted pyrrolidines as mGluR5 antagonists Hua Medicine (Shanghai) Ltd. 05/11/202D 3D TSV
US10328053 138 135 HGNC:10905 Substituted pyrrolizine compounds and uses thereof Gilead Sciences Inc 05/11/202D 3D TSV
US10323036 218 217 TYK2 inhibitors and uses thereof Nimbus Lakshmi, Inc. 05/11/202D 3D TSV
US10329273 24 22 HGNC:7045 Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors Bristol-Myers Squibb Co. 05/11/202D 3D TSV
US10328077 121 118 HGNC:29079 Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas Celgene Corporation 05/11/202D 3D TSV
US10000475 14 14 HGNC:10597 Triazine carboxamides as sodium channel blockers Purdue Pharma LP 05/11/202D 3D TSV
US10329280 3 3 HGNC:6307 Urea derivatives and uses thereof Kala Pharmaceuticals, Inc. 05/11/202D 3D TSV
US10322118 24 21 HGNC:3402 Compounds and methods for inhibiting Cif virulence factor Dartmouth College 05/10/202D 3D TSV
US10323016 48 24 HGNC:19680 Imidazol- or 1,2,4-triazol-derivatives and their use UNIVERSITE DE LILLE 2 DROIT ET SANTE 05/10/202D 3D TSV
US10323000 355 196 HGNC:5992 HGNC:8537 Indole derivatives and their use in neurodegenerative diseases Merck Patent GmbH 05/10/202D 3D TSV
US10322143 63 61 HGNC:220 HGNC:221 Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure UNIVERSITETET I OSLO 05/10/202D 3D TSV
US10322108 46 46 N-benzoate group substituted benzopyrroline-2-one derivative and use thereof Beijing Hanmi Pharmaceutical Co., Ltd. 05/10/202D 3D TSV
US10322140 24 13 HGNC:2637 HGNC:3537 Preparation and use of 7a-heterocycle substituted-6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists TBA 05/10/202D 3D TSV
US10323019 18 6 HGNC:6190 HGNC:6192 HGNC:6193 Pyrazolylaminobenzimidazole derivatives as JAK inhibitors Eli Lilly and Company 05/10/202D 3D TSV
US10323022 648 638 HGNC:8031 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors Array BioPharma Inc 05/10/202D 3D TSV
US10323018 229 227 HGNC:30092 Quinazoline and quinoline compounds and uses thereof Millennium Pharmaceuticals Inc 05/10/202D 3D TSV
US10323023 19 19 HGNC:10252 Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof Beijing Tide Pharmaceutical Co., Ltd 05/10/202D 3D TSV
US10323029 995 365 HGNC:3169 HGNC:3167 HGNC:3165 HGNC:14299 HGNC:3170 Sphinogosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders The Scripps Research Institute 05/10/202D 3D TSV
US10323020 15 13 HGNC:283 Substituted piperidinyl tetrahydroquinolines Bayer Pharma Aktiengesellschaft 05/10/202D 3D TSV
US10323021 206 114 HGNC:6251 Triazoles as NR2B receptor inhibitors JANSSEN PHARMACEUTICALS, INC. 05/10/202D 3D TSV
US9994571 22 11 HGNC:8154 HGNC:8156 10-substituted morphinan hydantoins Purdue Pharma LP 05/07/202D 3D TSV
US9993478 104 32 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6874 HGNC:6876 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors Respivert Ltd 05/05/202D 3D TSV
US9993465 57 10 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof Georgetown University 05/05/202D 3D TSV
US9994552 278 138 HGNC:6342 Compositions useful for treating disorders related to kit BLUEPRINT MEDICINES CORPORATION 05/05/202D 3D TSV
US9994546 130 129 HGNC:29079 Cyclopropylamines as LSD1 inhibitors Incyte Corporation 05/05/202D 3D TSV
US9994525 16 16 H3 antagonists containing phenoxypiperidine core structure Richter Gedeon Nyrt. 05/05/202D 3D TSV
US9994547 150 149 HGNC:11584 Heteroarylamide inhibitors of TBK1 Takeda Pharmaceutical Co., Ltd 05/05/202D 3D TSV
US9994550 8 8 HGNC:3594 Heterocyclic modulators of lipid synthesis for use against cancer and viral infections 3-V Biosciences, Inc. 05/05/202D 3D TSV
US9994590 59 54 HGNC:8772 Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors Sunovion Pharmaceuticals Inc 05/05/202D 3D TSV
US9994576 33 33 HGNC:1133 Substituted pyrazolo[3,4-d]pyrimidines as kinase inhibitors Principia Biopharma Inc 05/05/202D 3D TSV
US9993479 43 43 HGNC:8031 Trk-inhibiting compound Ono Pharmaceutical Co., Ltd 05/05/202D 3D TSV
US9988392 21 13 HGNC:8154 HGNC:8156 7-beta-alkyl analogs of orvinols Purdue Pharma LP 04/30/202D 3D TSV
US9987274 135 47 HGNC:11526 HGNC:11527 HGNC:11528 N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists Ogeda SA 04/30/202D 3D TSV
US9987255 48 24 HGNC:4849 HGNC:4848 5,5-bicyclic oxazole orexin receptor antagonists Merck Sharp & Dohme Corp 04/25/202D 3D TSV
US9987253 8 8 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes Jenrin Discovery Inc 04/25/202D 3D TSV
US9988375 36 33 Inhibitors of lysine gingipain CORTEXYME, INC. 04/25/202D 3D TSV
US9987259 31 31 HGNC:1960 Pharmaceutical composition comprising pyridone derivatives SK Biopharmaceuticals Co. Ltd 04/25/202D 3D TSV
US9987278 41 41 Pharmaceutical composition for treating FLT3 mutation-positive cancer, mutant FLT3 inhibitor and uses thereof FUJIFILM Corporation 04/25/202D 3D TSV
US9987252 5 5 Primary amines and derivitves thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto Arena Pharmaceuticals Inc 04/25/202D 3D TSV
US9987276 467 239 HGNC:1079 HGNC:6193 HGNC:6171 HGNC:3236 Substituted 2,4-diaminopyrimidines as kinase inhibitors Celgene CAR LLC 04/25/202D 3D TSV
US9981963 29 29 HGNC:1974 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors Janssen Pharmaceutica NV 04/18/202D 3D TSV
US9981944 245 124 HGNC:11773 GDF-8 inhibitors Rigel Pharmaceuticals, Inc 04/18/202D 3D TSV
US9981901 75 73 HGNC:3449 IRE-1α inhibitors FOSUN ORINOVE PHARMATECH, INC. 04/18/202D 3D TSV
US9981975 438 146 HGNC:7027 HGNC:12446 Pyrrolotriazine compounds as tam inhibitors Incyte Corporation 04/18/202D 3D TSV
US9981909 592 296 HGNC:5301 HGNC:11050 HGNC:5295 HGNC:5294 Serotonin receptor modulators Janssen Pharmaceutica NV 04/18/202D 3D TSV
US9981925 150 74 HGNC:391 HGNC:10436 Substituted benzo[d][1,2,3]triazines as p70S6K inhibitors Merck Patent GmbH 04/18/202D 3D TSV
US9981950 116 116 HGNC:6251 Triazoles as NR2B receptor inhibitors JANSSEN PHARMACEUTICALS, INC. 04/18/202D 3D TSV
US9981973 20 10 HGNC:11708 HGNC:6059 Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization NewLink Genetics Corporation 04/18/202D 3D TSV
US9980929 73 73 Trifluoromethylpropanamide derivatives Hoffman-La Roche Inc 04/18/202D 3D TSV
US10314832 18 17 HGNC:2514 β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators Samumed, LLC 04/15/202D 3D TSV
US10308635 23 23 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors Takeda Pharmaceutical Co., Ltd 04/15/202D 3D TSV
US10308629 47 40 HGNC:1148 1H-pyrrol-3-amines Bayer Pharma Aktiengesellschaft 04/15/202D 3D TSV
US10307427 23 18 HGNC:6857 Apoptosis signal-regulating kinase inhibitors Gilead Sciences Inc 04/15/202D 3D TSV
US10308636 80 80 HGNC:2843 Aromatic heterocyclic compound Mitsubishi Tanabe Pharma Corporation 04/15/202D 3D TSV
US10308660 171 170 HGNC:9644 Compounds and compositions for inhibiting the activity of SHP2 Novartis AG 04/15/202D 3D TSV
US10308607 3 3 HGNC:4006 Fucosidase inhibitors HORIZON ORPHAN LLC 04/15/202D 3D TSV
US10308628 10 10 HGNC:338 Heterocyclic compounds and methods for their use Novartis AG 04/15/202D 3D TSV
US10308644 271 267 Heterocyclic compounds as immunomodulators Incyte Corporation 04/15/202D 3D TSV
US10308615 344 163 Heterocyclic compounds as inhibitors of Vanin-1 enzyme Pfizer Inc 04/15/202D 3D TSV
US10308663 3 3 HGNC:9636 Inhibitors of PTP4A3 for the treatment of cancer University of Virginia Patent Foundation 04/15/202D 3D TSV
US10308648 15 15 HGNC:1778 Inhibitors of cyclin-dependent kinase 7 (CDK7) Syros Pharmaceuticals, Inc. 04/15/202D 3D TSV
US10314827 21 18 HGNC:441 Methods of use of cyclopamine analogs Infinity Pharmaceuticals Inc 04/15/202D 3D TSV
US10308620 74 74 HGNC:1950 Muscarinic M1 receptor positive allosteric modulators Suven Life Sciences Limited 04/15/202D 3D TSV
US10308667 168 167 HGNC:32311 Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors Boehringer Ingelheim International GmbH 04/15/202D 3D TSV
US10308645 86 43 HGNC:4849 HGNC:4848 Piperidine oxadiazole and thiadiazole orexin receptor antagonists Merck Sharp & Dohme Corp 04/15/202D 3D TSV
US10308654 32 18 HGNC:1722 Preparation and use of kinase inhibitor CHANGZHOU LONGTHERA PHARMACEUTICALS INC. 04/15/202D 3D TSV
US10308605 14 14 Proton pump inhibitors Takeda Pharmaceutical Co., Ltd 04/15/202D 3D TSV
US10308659 246 121 HGNC:2160 HGNC:2159 Pyridine derivatives Hoffmann-La Roche Inc 04/15/202D 3D TSV
US10307414 35 34 HGNC:1133 Pyridinyl and fused pyridinyl triazolone derivatives Takeda Pharmaceutical Co., Ltd 04/15/202D 3D TSV
US10308634 22 22 HGNC:17967 Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs Bayer Pharma Aktiengesellschaft 04/15/202D 3D TSV
US10307413 679 673 Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof Epizyme Inc 04/15/202D 3D TSV
US10307426 36 16 HGNC:6190 HGNC:6192 Therapeutic compounds and compositions, and methods of use thereof Genentech Inc 04/15/202D 3D TSV
US10308614 304 238 Therapeutic compounds and uses thereof Genentech Inc 04/15/202D 3D TSV
US10308637 319 310 HGNC:6863 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. 04/15/202D 3D TSV
US10308662 114 28 HGNC:8979 HGNC:8978 HGNC:8980 HGNC:8977 Thienopyranones as kinase and epigenetic inhibitors Signal Rx Pharmaceuticals Inc 04/15/202D 3D TSV
US10308652 64 60 HGNC:11892 Tricyclic heterocyclic compounds useful as inhibitors of TNF Bristol-Myers Squibb Co. 04/15/202D 3D TSV
US9975876 63 31 HGNC:4849 HGNC:4848 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists Merck Sharp & Dohme Corp 04/10/202D 3D TSV
US9974785 36 36 HGNC:5301 Aromatic heterocyclic derivatives and pharmaceutical applications thereof Sunshine Lake Pharma Co., Ltd 04/10/202D 3D TSV
US9975862 12 2 HGNC:3023 HGNC:5286 Arylpiperazine derivatives and methods of utilizing same Reviva Pharmaceuticals Inc 04/10/202D 3D TSV
US9975858 10 10 HGNC:10597 Benzimidazole derivatives and use thereof Purdue Pharma LP 04/10/202D 3D TSV
US9975854 3 3 HGNC:8154 Benzomorphan analogs and use thereof Purdue Pharma LP 04/10/202D 3D TSV
US9975902 13 11 HGNC:9257 Compounds for the inhibition of cyclophilins and uses thereof Merck Patent GmbH 04/10/202D 3D TSV
US9975861 11 4 HGNC:933 HGNC:4617 Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer''s disease FONDAZIONE ISTITUTO ITAIANO DI TECNOLOGIA 04/10/202D 3D TSV
US9975874 86 44 HGNC:6371 HGNC:3529 Factor XIa inhibitors Merck Sharp & Dohme Corp 04/10/202D 3D TSV
US9975882 212 63 HGNC:1079 HGNC:1133 HGNC:11719 HGNC:12434 Heteroaromatic compounds as BTK inhibitors Boehringer Ingelheim International GmbH 04/10/202D 3D TSV
US9975907 123 80 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Pyrimidinones as PI3K inhibitors Incyte Holdings Corporation 04/10/202D 3D TSV
US9969723 53 50 HGNC:4498 3-(4-(benzyloxy)phenyl)hex-4-ynoic acid derivative, method of preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient HYUNDAI PHARM CO., LTD 04/06/202D 3D TSV
US9969687 122 122 HGNC:1610 Compounds useful as CCR9 modulators Norgine B.V. 04/06/202D 3D TSV
US9969724 53 53 HGNC:3551 Factor IXa inhibitors Merck Sharp & Dohme Corp 04/06/202D 3D TSV
US9969749 169 166 HGNC:17967 Inhibitors of IRAK4 activity Merck Sharp & Dohme Corp 04/06/202D 3D TSV
US9969726 724 190 Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof Sanford-Burnham Medical Research Institute 04/06/202D 3D TSV
US9969738 28 6 HGNC:11526 HGNC:11527 HGNC:11528 N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders Ogeda SA 04/06/202D 3D TSV
US9969700 8 8 HGNC:8535 P2X4 receptor antagonist Nippon Chemiphar Co., Ltd 04/06/202D 3D TSV
US9968610 15 10 HGNC:6251 HGNC:2625 Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists Rugen Holdings (Cayman) Limited 04/06/202D 3D TSV
US9969686 9 9 HGNC:348 Synthesis of diindolylmethanes and indolo[3,2-b]carbazoles, compounds formed thereby, and pharmaceutical compositions containing them Wisconsin Alumni Research Foundation 04/06/202D 3D TSV
US9969743 260 130 HGNC:3023 HGNC:3024 Urea and amide derivatives of aminoalkylpiperazines and use thereof Southern Research Institute 04/06/202D 3D TSV
US9963460 3 1 HGNC:8153 HGNC:8154 HGNC:8156 Morphinan derivative University of Tsukuba 03/30/202D 3D TSV
US9963444 117 117 HGNC:736 N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof Northeastern University 03/30/202D 3D TSV
US9963434 220 220 N-arylmethyl sulfonamide negative modulators of NR2A Luc Therapeutics, Inc. 03/30/202D 3D TSV
US9963446 26 26 Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use Genentech Inc 03/30/202D 3D TSV
US9963456 40 40 HGNC:1373 Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd 03/30/202D 3D TSV
US9962388 45 45 HGNC:15631 Pyrrolopyrimidine compounds used as TLR7 agonist Chia Tai Tianqing Pharmaceutical Group Co., Ltd 03/30/202D 3D TSV
US9963443 13 13 Radiolabeled compounds Takeda Pharmaceutical Co., Ltd 03/30/202D 3D TSV
US9963439 46 18 HGNC:2637 HGNC:20581 HGNC:2603 HGNC:2622 HGNC:2623 Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase University of Washington Through its Center for Commercialization 03/30/202D 3D TSV
US9963453 45 43 HGNC:8157 Substituted pyrazino[1,2-a]indoles as sigma receptor activity modulators LABORATORIOS DEL DR. ESTEVE S.A. 03/30/202D 3D TSV
US9962398 60 15 HGNC:1373 HGNC:1383 HGNC:1371 HGNC:1368 Sulfonamide compounds for inhibition of metastatic tumor growth Welichem Biotech Inc. 03/30/202D 3D TSV
US9962362 18 12 HGNC:3521 HGNC:9642 Use of small molecule inhibitors targeting EYA tyrosine phosphatase Children''s Hospital Medical Center 03/30/202D 3D TSV
US10301320 27 25 HGNC:5154 Compositions and methods of modulating 15-PGDH activity University of Kentucky Research Foundation 03/26/202D 3D TSV
US10301305 252 63 Heteroaromatic derivatives and their use as pharmaceuticals Mutabilis 03/26/202D 3D TSV
US10301323 183 61 HGNC:4852 HGNC:4854 HGNC:4853 Histone deacetylase inhibitors BioMarin Pharmaceutical Inc 03/26/202D 3D TSV
US10301291 31 31 HGNC:6872 Imidazole derivative having JNK inhibitory activity and use thereof SAMJIN PHARMACEUTICAL CO., LTD. 03/26/202D 3D TSV
US10301317 373 365 HGNC:6871 Inhibitors of ERK and methods of use Kura Oncology Inc 03/26/202D 3D TSV
US10301288 61 15 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 Kinase inhibitors Topivert Pharma Limited 03/26/202D 3D TSV
US10301336 33 33 HGNC:2771 Phosphonate compounds for treatment of complement mediated disorders Achillion Pharmaceuticals Inc 03/26/202D 3D TSV
US10301286 79 33 HGNC:6932 HGNC:6929 HGNC:6931 Piperazine derivative Astellas Pharma Inc 03/26/202D 3D TSV
US10301306 185 180 HGNC:10021 Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors Bristol-Myers Squibb Co. 03/26/202D 3D TSV
US10301297 63 62 HGNC:1133 Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease Guangzhou Innocare Pharma Tech Co., Ltd. 03/26/202D 3D TSV
US10301284 141 139 HGNC:6371 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. 03/26/202D 3D TSV
US10301278 58 54 HGNC:9644 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 Novartis AG 03/25/202D 3D TSV
US10300056 14 14 HGNC:9843 CGRP receptor antagonists Heptares Therapeutics Limited 03/25/202D 3D TSV
US10301272 844 306 Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] Phenex Pharmaceuticals AG 03/25/202D 3D TSV
US10301280 257 153 HGNC:6342 Compounds and methods for kinase modulation, and indications therefor Plexxikon Inc. 03/25/202D 3D TSV
US10300051 61 61 HGNC:29079 Cyclopropylamines as LSD1 inhibitors Incyte Corporation 03/25/202D 3D TSV
US10301269 41 41 HGNC:3827 Imidazole derivatives as formyl peptide receptor modulators Allergan Inc 03/25/202D 3D TSV
US10300066 119 118 HGNC:1133 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors Zhejiang DTRM Biopharma Co. Ltd 03/25/202D 3D TSV
US10300067 53 53 HGNC:644 Tetrahydropyridopyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd 03/25/202D 3D TSV
US10301253 203 87 HGNC:29079 Therapeutic compounds and uses thereof Genentech Inc 03/25/202D 3D TSV
US10300048 73 53 HGNC:3553 Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation UNIVERSITAT BERN 03/25/202D 3D TSV
US10300060 43 43 HGNC:8031 Trk-inhibiting compound Ono Pharmaceutical Co., Ltd 03/25/202D 3D TSV
US10300058 50 18 HGNC:3236 Tyrosine kinase inhibitor and uses thereof Xuanzhu Pharma Co., Ltd 03/25/202D 3D TSV
US10300074 114 40 HGNC:13702 Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy Sanford Burnham Prebys Medical Discovery Institute 03/25/202D 3D TSV
US9957268 196 88 1H-pyrrolo[2,3,c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins Incyte Corporation 03/23/202D 3D TSV
US9956214 208 103 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum University of Washington Through its Center for Commercialization 03/23/202D 3D TSV
US9957261 118 59 6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives Hoffman-La Roche Inc 03/23/202D 3D TSV
US9957235 248 139 Benzimidazol-2-amines as mIDH1 inhibitors Bayer Pharma Aktiengesellschaft 03/23/202D 3D TSV
US9957263 371 184 HGNC:13575 Bromodomain inhibitors AbbVie Inc 03/23/202D 3D TSV
US9957276 44 44 HGNC:1771 CDK inhibitors GI Therapeutics, Inc. 03/23/202D 3D TSV
US9956208 4 4 HGNC:1133 Compounds for the treatment of cancer and inflammatory diseases TBA 03/23/202D 3D TSV
US9957264 938 423 HGNC:6190 HGNC:6192 Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors Merck Sharp & Dohme Corp 03/23/202D 3D TSV
US9957265 226 75 HGNC:6190 HGNC:6192 N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors Merck Sharp & Dohme Corp 03/23/202D 3D TSV
US9956192 42 21 HGNC:4852 HGNC:14064 Selective histone deactylase 6 inhibitors H. Lee Moffitt Cancer Center and Research Institute Inc 03/23/202D 3D TSV
US9951056 63 61 HGNC:1133 Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease Beijing Innocare Pharma Tech Co., Ltd. 03/18/202D 3D TSV
US9951063 147 147 HGNC:4540 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives IDORSIA PHARMACEUTICALS Ltd 03/16/202D 3D TSV
US9951077 118 116 HGNC:1133 Aminopyridazinone compounds as protein kinase inhibitors Jiangsu Hengrui Medicine Co., Ltd. 03/16/202D 3D TSV
US9951027 390 346 Benzimidazol-2-amines as MIDH1 inhibitors Bayer Pharma Aktiengesellschaft 03/16/202D 3D TSV
US9951071 443 219 HGNC:6371 HGNC:3529 Dihydropyridone P1 as factor XIa inhibitors Bristol-Myers Squibb Co. 03/16/202D 3D TSV
US9951026 13 13 HGNC:3357 Heterocyclic vinyl autotaxin inhibitor compounds PharmAkea Inc 03/16/202D 3D TSV
US9951086 310 305 HGNC:17967 Indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments Bayer Pharma Aktiengesellschaft 03/16/202D 3D TSV
US9949975 25 25 HGNC:933 Inhibitors of beta-secretase Vitae Pharmaceuticals Inc 03/16/202D 3D TSV
US9951048 488 236 HGNC:4617 HGNC:3091 Isoquinolin-3-yl carboxamides and preparation and use thereof Samumed, LLC 03/16/202D 3D TSV
US9951014 113 35 HGNC:7872 HGNC:7873 Mammalian and bacterial nitric oxide synthase inhibitors Northwestern University 03/16/202D 3D TSV
US9949951 29 28 HGNC:6059 Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors iTeos Therapeutics 03/16/202D 3D TSV
US9951035 6 3 HGNC:7175 HGNC:7176 Selective matrix metalloproteinase inhibitors University of Notre Dame du Lac 03/16/202D 3D TSV
US9951029 63 63 HGNC:3765 Styryl quinazoline derivatives as pharmaceutically active agents Vichem Chemie Kutató 03/16/202D 3D TSV
US9951033 23 23 Tertiary amines for use in the treatment of cardiac disorders UNIVERSITETET I OSLO 03/16/202D 3D TSV
US9944601 159 43 HGNC:6833 HGNC:6834 HGNC:29079 (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors Oryzon Genomics, S.A. 03/12/202D 3D TSV
US9944646 114 109 HGNC:8977 Bicyclic azaheterocyclobenzylamines as PI3K inhibitors Incyte Holdings Corporation 03/12/202D 3D TSV
US9944606 9 5 HGNC:2160 HGNC:2159 Cannabinoid receptor modulators Arena Pharmaceuticals Inc 03/12/202D 3D TSV
US9944643 8 8 HGNC:3529 Factor XIa inhibitors Merck Sharp & Dohme Corp 03/12/202D 3D TSV
US9944647 138 138 HGNC:29079 Heterocyclic compounds as LSD1 inhibitors Incyte Corporation 03/12/202D 3D TSV
US9944645 205 205 HGNC:7029 Imidazotriazines and imidazopyrimidines as kinase inhibitors Incyte Corporation 03/12/202D 3D TSV
US9944618 940 167 HGNC:6251 HGNC:11050 HGNC:2637 HGNC:2625 HGNC:11048 HGNC:11049 Inhibiting neurotransmitter reuptake Mayo Foundation 03/12/202D 3D TSV
US9943516 19 17 HGNC:17967 Inhibitors of IRAK4 activity Merck Sharp & Dohme Corp 03/12/202D 3D TSV
USRE46792 103 103 HGNC:8783 Oxazole compound and pharmaceutical composition Otsuka Pharmaceutical Co., Ltd 03/12/202D 3D TSV
US9944624 126 61 HGNC:17432 HGNC:1936 Substituted amino triazoles useful as human chitinase inhibitors OncoArendi Therapeutics SA 03/12/202D 3D TSV
US10294221 63 57 1, 3, 4-thiadiazole compounds and their use in treating cancer AstraZeneca AB 03/10/202D 3D TSV
US10294230 48 11 HGNC:4586 HGNC:6251 HGNC:2625 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists Rugen Holdings (Cayman) Limited 03/10/202D 3D TSV
US10294218 165 150 HGNC:1780 4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity VIROSTATICS SRL 03/10/202D 3D TSV
US10294227 332 21 HGNC:11283 HGNC:12841 HGNC:9617 HGNC:8803 HGNC:4840 HGNC:6735 HGNC:3697 HGNC:4037 HGNC:1057 HGNC:76 HGNC:6342 HGNC:3955 HGNC:3942 HGNC:9967 HGNC:6524 Compounds UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH 03/10/202D 3D TSV
US10292975 2 2 Compounds as rearranged during transfection (RET) inhibitors GlaxoSmithKline 03/10/202D 3D TSV
US10294217 35 27 HGNC:1950 Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators Suven Life Sciences Limited 03/10/202D 3D TSV
US10294229 444 398 HGNC:17967 Heteroaryl substituted aminopyridine compounds Bristol-Myers Squibb Co. 03/10/202D 3D TSV
US10294212 277 273 HGNC:27269 HGNC:6059 Inhibitors of the kynurenine pathway CURADEV PHARMA, PVT. LTD. 03/10/202D 3D TSV
US10292981 53 47 HGNC:6001 Oxazoline and isoxazoline derivatives as CRAC modulators LUPIN LIMITED 03/10/202D 3D TSV
US10294259 6 3 HGNC:11037 HGNC:11036 Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof Tianjin Institute of Pharmaceutical Research 03/10/202D 3D TSV
US10294214 80 80 HGNC:6932 Positive allosteric modulators of human melanocortin-4 receptor Vanderbilt University 03/10/202D 3D TSV
US10294223 197 129 HGNC:3689 HGNC:3688 Quinolone derivatives as fibroblast growth factor receptor inhibitors Principia Biopharma Inc 03/10/202D 3D TSV
US10294226 60 15 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:12440 Small molecule inhibitors of the JAK family of kinases Janssen Pharmaceutica NV 03/10/202D 3D TSV
US10294246 271 135 HGNC:9542 HGNC:9545 Substituted boronic acids and boronate esters as immunoproteasome inhibitors Merck Patent GmbH 03/10/202D 3D TSV
US10292985 72 36 HGNC:11773 TGF beta receptor antagonists Bristol-Myers Squibb Co. 03/10/202D 3D TSV
US9938265 43 33 1,3,4-thiadiazole compounds and their use in treating cancer AstraZeneca AB 03/02/202D 3D TSV
US9938276 164 81 HGNC:4849 HGNC:4848 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists Merck Sharp & Dohme Corp 03/02/202D 3D TSV
US9938268 34 34 HGNC:11393 C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof Merck Patent GmbH 03/02/202D 3D TSV
US9938222 129 116 HGNC:19061 Cyclopropanecarboxylic acid GPR120 modulators Bristol-Myers Squibb Co. 03/02/202D 3D TSV
US9938267 694 668 Heterocyclic inhibitors of glutaminase Calithera Biosciences Inc 03/02/202D 3D TSV
US9938272 109 34 HGNC:9475 HGNC:3528 HGNC:3535 Hydrazine compound as blood coagulation factor Xa inhibitor North China Pharmaceutical Company., Ltd. 03/02/202D 3D TSV
US9938274 44 22 HGNC:6307 HGNC:7029 Naphthyridine compounds, medical combinations and use thereof NANJING NATINEFY PHARMATECH CO., LTD. 03/02/202D 3D TSV
US9938257 57 25 HGNC:6190 HGNC:6192 HGNC:11393 HGNC:11390 HGNC:3765 Substituted heteroaryl compounds and methods of use CALITOR SCIENCES, LLC 03/02/202D 3D TSV
US9938289 9 9 Therapeutic pyrazolyl thienopyridines FBM THERAPEUTICS, LLC 03/02/202D 3D TSV
US9938290 52 13 HGNC:8978 HGNC:8975 HGNC:8977 HGNC:8976 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors Karus Therapeutics Limited 03/02/202D 3D TSV
US10287286 262 260 HGNC:14660 Compounds Takeda Pharmaceutical Co., Ltd 02/29/202D 3D TSV
US9931340 68 66 HGNC:2671 Pyridazinone compounds and their use as DAAO inhibitors Takeda Pharmaceutical Co., Ltd 02/29/202D 3D TSV
US10285983 70 70 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof Samumed, LLC 02/27/202D 3D TSV
US10285982 66 66 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof Samumed, LLC 02/27/202D 3D TSV
US10287274 43 43 HGNC:5302 5-hydroxytryptamine receptor 7 activity modulators and their method of use TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 02/27/202D 3D TSV
US10287270 3 3 HGNC:550 Amino pyrimidine SSAO inhibitors Eli Lilly and Company 02/27/202D 3D TSV
US10287301 719 698 HGNC:2771 Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders Achillion Pharmaceuticals Inc 02/27/202D 3D TSV
US10287293 45 22 Bicyclic heterocyclic compounds as PDE2 inhibitors Merck Sharp & Dohme Corp 02/27/202D 3D TSV
US10287292 184 129 HGNC:23692 CXCR7 antagonists ChemoCentryx, Inc. 02/27/202D 3D TSV
US10287258 37 37 HGNC:2528 Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors AstraZeneca AB 02/27/202D 3D TSV
US10287278 40 14 HGNC:6026 HGNC:6027 Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies Galderma Research & Development 02/27/202D 3D TSV
US10285988 30 30 HGNC:15983 Compounds for treatment of fibrosis diseases CUREGENIX, INC. 02/27/202D 3D TSV
US10287300 130 64 HGNC:28426 Heterocyclic derivatives as modulators of kinase activity Merck Patent GmbH 02/27/202D 3D TSV
US10287268 8 4 HGNC:4840 HGNC:1133 Imidazolyl kinase inhibitors and uses thereof Dana-Farber Cancer Institute Inc 02/27/202D 3D TSV
US10287279 42 39 HGNC:433 Inhibitors of human 12/15-lipoxygenase THE CHILDREN'S HOSPITAL CORPORATION 02/27/202D 3D TSV
US10287267 951 304 HGNC:4617 HGNC:3091 Isoquinolin-3-yl carboxamides and preparation and use thereof Samumed, LLC 02/27/202D 3D TSV
US10287250 110 35 HGNC:8156 Morphan and morphinan analogues, and methods of use ALKERMES PHARMA IRELAND LIMITED 02/27/202D 3D TSV
US10285989 371 197 Pyrimidinone amide compounds as PDE2 inhibitors Merck Sharp & Dohme Corp 02/27/202D 3D TSV
US10287272 149 126 Substituted indazole compounds as RORgammaT inhibitors and uses thereof Merck Sharp & Dohme Corp 02/27/202D 3D TSV
US10287305 266 261 HGNC:4849 Substituted piperidine compound and use thereof Takeda Pharmaceutical Co., Ltd 02/27/202D 3D TSV
US10287253 52 51 HGNC:15631 Substituted pyrimidines containing acidic groups as TLR7 modulators APROS THERAPEUTICS, INC. 02/27/202D 3D TSV
US10287295 605 303 HGNC:11773 TGF-β inhibitors Rigel Pharmaceuticals, Inc 02/27/202D 3D TSV
US10280166 126 125 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof Samumed, LLC 02/24/202D 3D TSV
US9932329 28 14 HGNC:6171 HGNC:12434 Benzimidazole derivatives as RLK and ITK inhibitors Principia Biopharma Inc 02/24/202D 3D TSV
US9932325 215 166 Compounds, compositions, and methods Denali Therapeutics Inc. 02/24/202D 3D TSV
US9932332 2 2 HGNC:7967 FXR (NR1H4) modulating compounds Gilead Sciences Inc 02/24/202D 3D TSV
US10280171 183 98 HGNC:3255 Heterocyclic inhibitors of PTPN11 The University of Texas System 02/24/202D 3D TSV
US10280184 71 69 HGNC:1133 Heterocyclic kinase inhibitors AbbVie Inc 02/24/202D 3D TSV
US9932350 108 101 HGNC:17967 Inhibitors of IRAK4 activity Merck Sharp & Dohme Corp 02/24/202D 3D TSV
US10280167 39 39 Purine derivatives for the treatment of viral infections Janssen Ireland 02/24/202D 3D TSV
US9932327 10 5 HGNC:1780 HGNC:1771 Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof The Council of Scientific & Industrial Research 02/24/202D 3D TSV
US9931338 7 7 HGNC:11491 Syk inhibitors Gilead Sciences Inc 02/24/202D 3D TSV
US9932341 125 112 HGNC:8977 Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders Incyte Corporation 02/24/202D 3D TSV
US10278968 15 15 Combination therapy with glutaminase inhibitors Calithera Biosciences Inc 02/21/202D 3D TSV
US10278929 41 36 HGNC:12405 Identification of stabilizers of multimeric proteins The Board of Trustees of the Leland Stanford Junior University 02/21/202D 3D TSV
US10280160 31 26 HGNC:1884 Phthalazinone compounds and methods for the treatment of cystic fibrosis Flatley Discovery Lab LLC 02/21/202D 3D TSV
US10280164 16 16 HGNC:6863 Pyrazolopyridone compounds and uses thereof Incyte Corporation 02/21/202D 3D TSV
US10280144 213 213 Pyridazine derivatives as RORc modulators Genentech Inc 02/21/202D 3D TSV
US10280165 40 40 Pyridopyrimidinones and methods of use thereof Genentech Inc 02/21/202D 3D TSV
US10280150 297 183 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors FORMA TM2, INC. 02/21/202D 3D TSV
US10280174 3 2 HGNC:1133 HGNC:3236 Salt of fused pyrimidine compound and crystal thereof Taiho Pharmaceutical Co., Ltd 02/21/202D 3D TSV
US10278975 186 172 HGNC:6871 Serine/threonine kinase inhibitors Genentech Inc 02/21/202D 3D TSV
US10280149 220 219 HGNC:13610 Therapeutic compounds and uses thereof Genentech Inc 02/21/202D 3D TSV
US10278962 24 11 HGNC:11177 HGNC:11178 Tricyclic analogues, preparation method and uses thereof Shanghai Institute of Materia Medica, Chinese Academy of Sciences 02/21/202D 3D TSV
US10273234 26 26 HGNC:3357 Compounds that are S1P modulating agents and/or ATX modulating agents BIOGEN MA INC. 02/20/202D 3D TSV
US10273222 604 163 HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 Histone demethylase inhibitors CELGENE QUANTSCEL RESEARCH, INC. 02/20/202D 3D TSV
US10272074 477 475 HGNC:7978 Inhibitors of glucocorticoid receptor translocation Sanford Burnham Prebys Medical Discovery Institute 02/20/202D 3D TSV
US10273211 24 5 HGNC:3763 HGNC:6307 HGNC:11390 HGNC:3767 HGNC:7029 HGNC:9967 HGNC:3765 Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Exelixis Inc 02/20/202D 3D TSV
US10272079 361 180 HGNC:11073 NHE3-binding compounds and methods for inhibiting phosphate transport ARDELYX, INC. 02/20/202D 3D TSV
US10272095 87 83 HGNC:2874 NRF2 regulators GlaxoSmithKline 02/20/202D 3D TSV
US10272077 14 14 Piperidinone carboxamide azaindane CGRP receptor antagonists Merck Sharp & Dohme Corp 02/20/202D 3D TSV
US10272087 50 8 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Pteridines as FGFR inhibitors Astex Therapeutics Ltd 02/20/202D 3D TSV
US10273225 22 21 HGNC:4515 Pyrazines as modulators of GPR6 Takeda Pharmaceutical Co., Ltd 02/20/202D 3D TSV
US10273223 391 389 HGNC:3527 Substituted 6,5-fused bicyclic heteroaryl compounds Epizyme Inc 02/20/202D 3D TSV
US10273244 348 173 HGNC:3023 HGNC:3024 Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators Indivior UK Limited 02/20/202D 3D TSV
US10273230 16 15 HGNC:19061 Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof Piramal Enterprises Limited 02/20/202D 3D TSV
US10273214 78 39 HGNC:4588 HGNC:4587 HGNC:4586 Subunit selective NMDA receptor potentiators for the treatment of neurological conditions Emory University 02/20/202D 3D TSV
US10273259 881 804 Tricyclic sulfones as RORγ modulators Bristol-Myers Squibb Co. 02/20/202D 3D TSV
US9890168 32 15 HGNC:3236 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 02/16/202D 3D TSV
US9890171 200 130 HGNC:2592 Aldosterone synthase inhibitors Boehringer Ingelheim International GmbH 02/16/202D 3D TSV
US9890124 46 23 HGNC:15631 HGNC:15632 Benzazepine sulfonamide compounds Hoffmann-La Roche Inc 02/16/202D 3D TSV
US9890162 156 52 HGNC:19310 HGNC:8987 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors Incyte Corporation 02/16/202D 3D TSV
US9890156 152 37 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 02/16/202D 3D TSV
US9890160 3 3 HGNC:550 Compounds I Proximagen Limited 02/16/202D 3D TSV
US9890166 638 168 HGNC:13575 HGNC:1103 HGNC:2348 HGNC:1104 Imidazopyrrolidine derivatives and their use in the treatment of disease Novartis AG 02/16/202D 3D TSV
US9890185 468 169 HGNC:11491 HGNC:11283 HGNC:4616 HGNC:6876 Urea derivatives useful as kinase inhibitors Respivert Limited 02/16/202D 3D TSV
US9926281 1937 451 HGNC:7160 HGNC:195 HGNC:7155 HGNC:7166 HGNC:7159 HGNC:221 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis Galapagos NV 02/10/202D 3D TSV
US9926301 28 13 Bipyrazole derivatives as JAK inhibitors Incyte Corporation 02/10/202D 3D TSV
US9926306 34 33 Inhibition of MCL-1 and/or BFL-1/A1 Dana-Farber Cancer Institute Inc 02/10/202D 3D TSV
US9926330 55 53 HGNC:17967 Inhibitors of IRAK4 activity Merck Sharp & Dohme Corp 02/10/202D 3D TSV
US9926299 34 34 HGNC:1133 Inhibitors of bruton's tyrosine kinase Centaurus BioPharma Co., Ltd 02/10/202D 3D TSV
US9926282 826 401 HGNC:10251 HGNC:10252 Phthalazinones and isoquinolinones as rock inhibitors Bristol-Myers Squibb Co. 02/10/202D 3D TSV
US9926318 58 53 HGNC:3357 Tetracyclic autotaxin inhibitors PharmAkea Inc 02/10/202D 3D TSV
USRE47351 11 11 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists Gilead Sciences Inc 02/07/202D 3D TSV
US10266528 23 22 HGNC:1133 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof Merck Patent GmbH 02/07/202D 3D TSV
US10266537 116 27 HGNC:6613 HGNC:3763 HGNC:11724 HGNC:6735 HGNC:4037 HGNC:3386 HGNC:5960 HGNC:6859 HGNC:9829 HGNC:3689 HGNC:6873 HGNC:7027 HGNC:3767 HGNC:2730 HGNC:7029 HGNC:3688 HGNC:2731 HGNC:6192 HGNC:8031 HGNC:12841 HGNC:9617 HGNC:8803 HGNC:4840 HGNC:3430 HGNC:6307 HGNC:1079 HGNC:1057 HGNC:1133 HGNC:3395 HGNC:77 HGNC:1097 HGNC:76 HGNC:3393 HGNC:3955 HGNC:3236 HGNC:2444 HGNC:1974 HGNC:6524 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof St. Chuan University 02/07/202D 3D TSV
US10265310 158 71 HGNC:3827 HGNC:3826 6-membered cyclic amines or lactames substituted with urea and phenyl GRÜNENTHAL GMBH 02/07/202D 3D TSV
US10266550 64 26 HGNC:11986 HGNC:11989 Bacterial topoisomerase I inhibitors with antibacterial activity THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES 02/07/202D 3D TSV
US10259818 114 109 HGNC:8977 Bicyclic azaheterocyclobenzylamines as PI3K inhibitors Incyte Corporation 02/07/202D 3D TSV
US10266560 65 64 HGNC:7967 Bile acid analogs as FXR/TGR5 agonists and methods of use thereof Enanta Pharmaceuticals Inc 02/07/202D 3D TSV
US10259776 16 13 HGNC:4685 Branched 3-phenylpropionic acid derivatives and their use Bayer Intellectual Property GmbH 02/07/202D 3D TSV
US10266513 190 134 HGNC:1133 HGNC:3236 Bruton's tyrosine kinase inhibitors Pfizer Inc 02/07/202D 3D TSV
US10266491 200 168 HGNC:1133 Carbazole derivatives Bristol-Myers Squibb Co. 02/07/202D 3D TSV
US10266496 160 118 HGNC:12805 HGNC:17989 Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof Sunshine Lake Pharma Co., Ltd 02/07/202D 3D TSV
US10259816 26 26 HGNC:427 Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. 02/07/202D 3D TSV
US10266542 19 18 HGNC:3527 EZH2 inhibitors Mirati Therapeutics Inc 02/07/202D 3D TSV
US10266535 56 29 HGNC:1133 HGNC:3765 Inhibitor of FLT3 kinase and use thereof HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES 02/07/202D 3D TSV
US10259786 8 4 HGNC:3023 Psychotropic agents and uses thereof LB PHARMACEUTICALS INC. 02/07/202D 3D TSV
US10266526 956 932 HGNC:20982 Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer Epizyme Inc 02/07/202D 3D TSV
US10266548 211 187 HGNC:1148 Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases Bayer Intellectual Property GmbH 02/07/202D 3D TSV
US10259811 517 258 HGNC:11584 HGNC:14552 Tank-binding kinase inhibitor compounds Gilead Sciences Inc 02/07/202D 3D TSV
US10266515 202 144 HGNC:6371 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. 02/07/202D 3D TSV
US10265307 324 106 HGNC:19310 HGNC:8987 Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors Incyte Corporation 02/07/202D 3D TSV
US10266493 71 70 HGNC:17989 Thioacetate compounds, compositions and methods of use Ardea Biosciences, Inc. 02/07/202D 3D TSV
US10266549 345 343 HGNC:12558 ULK1 inhibitors and methods using same Salk Institute 02/07/202D 3D TSV
US9918985 181 155 Compounds and their use as BACE inhibitors AstraZeneca AB 02/04/202D 3D TSV
US9920047 375 109 HGNC:6833 HGNC:6834 HGNC:29079 Cyclopropanamine compound and use thereof Takeda Pharmaceutical Co., Ltd 02/04/202D 3D TSV
US9920032 510 168 HGNC:19310 HGNC:8987 Heterocyclic compounds useful as pim kinase inhibitors Incyte Corporation 02/04/202D 3D TSV
US9920031 261 218 HGNC:1133 Indole carboxamide compounds Bristol-Myers Squibb Co. 02/04/202D 3D TSV
US9920038 62 30 HGNC:4849 Methyl oxazole orexin receptor antagonists Merck Sharp & Dohme Corp 02/04/202D 3D TSV
US9920054 104 104 Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof Pfizer Inc 02/04/202D 3D TSV
US9920053 130 35 HGNC:6251 HGNC:11050 HGNC:11048 HGNC:11049 N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system CHRONOS THERAPEUTICS LIMITED 02/04/202D 3D TSV
US9920060 80 79 HGNC:3430 Pyrazolo[3,4-d]pyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd 02/04/202D 3D TSV
US9918974 2 2 Pyridone derivatives as rearranged during transfection (RET) kinase inhibitors GlaxoSmithKline 02/04/202D 3D TSV
US9918969 16 14 HGNC:3529 Substituted oxopyridine derivatives and use thereof as factor XIa/plasma Bayer Pharma Aktiengesellschaft 02/04/202D 3D TSV
US9918990 226 111 HGNC:13575 HGNC:1103 Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors Incyte Corporation 02/04/202D 3D TSV
US9914735 391 78 HGNC:11491 HGNC:11390 HGNC:4617 HGNC:3765 Heteroaryl Syk inhibitors Boehringer Ingelheim International GmbH 01/30/202D 3D TSV
US9914707 30 30 HGNC:6307 Naphthylamide compound, preparation method and use thereof Shanghai Institute of Materia Medica, Chinese Academy of Sciences 01/30/202D 3D TSV
US9914731 293 156 HGNC:7029 Pyrazolo[1,5-a]pyridine derivatives and methods of their use IGNYTA, INC. 01/30/202D 3D TSV
US9914736 114 113 HGNC:8031 TrKA kinase inhibitors, compositions and methods thereof Merck Sharp & Dohme Corp 01/30/202D 3D TSV
US9914740 420 404 HGNC:10252 Tricyclic pyrido-carboxamide derivatives as rock inhibitors Bristol-Myers Squibb Co. 01/30/202D 3D TSV
US9914721 22 11 HGNC:4849 HGNC:4848 Use of benzimidazole-proline derivatives IDORSIA PHARMACEUTICALS Ltd 01/30/202D 3D TSV
US9908875 45 45 HGNC:6857 Apoptosis signal-regulating kinase inhibitors Gilead Sciences Inc 01/27/202D 3D TSV
US9908845 68 65 HGNC:12680 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. 01/27/202D 3D TSV
US9908886 266 132 HGNC:7110 HGNC:7111 Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof Agency for Science, Technology and Research 01/27/202D 3D TSV
US9908899 143 48 HGNC:4852 HGNC:4854 HGNC:4853 Histone deacetylase inhibitors BioMarin Pharmaceutical Inc 01/27/202D 3D TSV
US9908865 511 154 HGNC:22978 HGNC:9886 HGNC:17071 HGNC:18039 HGNC:13610 Histone demethylase inhibitors Celgene Quanticel Research Inc 01/27/202D 3D TSV
US9907800 460 198 HGNC:11393 HGNC:11390 HGNC:11397 HGNC:3765 Kinase inhibitors and method of treating cancer University Health Network 01/27/202D 3D TSV
US9908872 19 8 HGNC:1133 HGNC:4195 HGNC:7972 Methods to treat lymphoplasmacytic lymphoma Dana-Farber Cancer Institute Inc 01/27/202D 3D TSV
US9908897 306 84 HGNC:6251 HGNC:11050 HGNC:11048 HGNC:11049 Spirocyclic derivatives CHRONOS THERAPEUTICS LIMITED 01/27/202D 3D TSV
US9908895 196 88 HGNC:6190 HGNC:6192 Tricyclic fused thiophene derivatives as JAK inhibitors Incyte Corporation 01/27/202D 3D TSV
US10246444 134 32 HGNC:3432 HGNC:3430 HGNC:3236 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions SABILA BIOSCIENCES LLC 01/21/202D 3D TSV
US10246442 135 135 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors Janssen Pharmaceutica NV 01/21/202D 3D TSV
US10253018 41 41 HGNC:6857 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Enanta Pharmaceuticals Inc 01/21/202D 3D TSV
US9896418 68 65 HGNC:12680 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. 01/21/202D 3D TSV
US9903855 20 5 HGNC:5960 HGNC:11584 HGNC:14552 HGNC:1974 Assays for screening for or identifying an agent or molecule that can block or inhibit AVB3 integrin from forming a complex with KRAS The Regents of the University of California 01/21/202D 3D TSV
US9896444 175 101 Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 Novartis AG 01/21/202D 3D TSV
US10246453 1146 330 HGNC:10593 HGNC:10585 HGNC:10596 Benzenesulfonamide compounds and their use as therapeutic agents Xenon Pharmaceuticals Inc 01/21/202D 3D TSV
US9902722 237 234 HGNC:19679 Biaryl kinase inhibitors Bristol-Myers Squibb Co. 01/21/202D 3D TSV
US10251892 856 186 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Bicyclic heterocycles as FGFR4 inhibitors Incyte Corporation 01/21/202D 3D TSV
US10246462 92 88 HGNC:1605 Chemokine receptor modulators and uses thereof FLX BIO, INC. 01/21/202D 3D TSV
US9896458 251 243 Compounds, compositions and methods Denali Therapeutics Inc. 01/21/202D 3D TSV
US10253017 22 9 HGNC:7856 HGNC:263 HGNC:264 Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors Palobiofarma, S.L. 01/21/202D 3D TSV
US10246466 54 18 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:8031 HGNC:8032 HGNC:8033 HGNC:427 Diaryl macrocycles as modulators of protein kinases TP Therapeutics, Inc. 01/21/202D 3D TSV
US9895376 116 57 Fused tricyclic compounds as Raf kinase inhibitors BeiGene, Ltd 01/21/202D 3D TSV
US9896436 329 106 HGNC:29012 HGNC:13606 HGNC:17071 HGNC:18039 HGNC:20672 HGNC:13610 Histone demethylase inhibitors Celgene Quanticel Research Inc 01/21/202D 3D TSV
US10246456 686 509 HGNC:17967 IRAK4 inhibiting agents BIOGEN MA INC. 01/21/202D 3D TSV
US10253004 54 53 HGNC:4498 Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof Boehringer Ingelheim International GmbH 01/21/202D 3D TSV
US10246457 56 28 HGNC:1133 Indazole and azaindazole Btk inhibitors Merck Sharp & Dohme Corp 01/21/202D 3D TSV
US10252984 51 51 HGNC:4545 Inhibiting G protein coupled receptor 6 kinase polypeptides Mayo Foundation 01/21/202D 3D TSV
US9902719 31 31 HGNC:29079 Inhibitors of lysine specific demethylase-1 Celgene Quanticel Research Inc 01/21/202D 3D TSV
US9902741 68 46 HGNC:8031 Macrocyclic compounds as TRK kinase inhibitors Array BioPharma Inc 01/21/202D 3D TSV
US10251893 230 227 HGNC:15983 N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators Novartis AG 01/21/202D 3D TSV
US9896435 31 31 HGNC:8031 N-pyrrolidinyl,N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors Array BioPharma Inc 01/21/202D 3D TSV
US9902709 13 13 HGNC:6307 Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition PEKING UNIVERSITY FOUNDER GROUP CO., LTD. 01/21/202D 3D TSV
US10253015 169 85 Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors FORMA TM2, INC. 01/21/202D 3D TSV
US9902726 5 4 HGNC:8154 HGNC:8156 Pyridone-sulfone morphinan analogs as opioid receptor ligands Purdue Pharma LP 01/21/202D 3D TSV
US9902714 35 7 HGNC:6307 HGNC:3690 HGNC:3691 HGNC:3689 HGNC:3688 Quinoxaline derivatives useful as FGFR kinase modulators Astex Therapeutics Ltd 01/21/202D 3D TSV
US10246467 67 57 Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors Boehringer Ingelheim International GmbH 01/21/202D 3D TSV
US9902710 169 168 HGNC:8772 Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) Exonhit Therapeutics, SA 01/21/202D 3D TSV
US9896452 703 365 HGNC:4849 HGNC:4848 Substituted prolines/piperidines as orexin receptor antagonists EOLAS THERAPEUTICS, INC. 01/21/202D 3D TSV
US10251889 530 232 HGNC:6190 HGNC:6192 HGNC:6193 HGNC:8031 HGNC:12440 Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors Array BioPharm Inc. 01/21/202D 3D TSV
US10253019 1854 609 HGNC:6192 HGNC:11584 HGNC:14552 Tank-binding kinase inhibitor compounds Gilead Sciences Inc 01/21/202D 3D TSV
US9896447 46 46 HGNC:8031 TrkA kinase inhibitors, compositions and methods thereof Merck Sharp & Dohme Corp 01/21/202D 3D TSV
US10238658 120 32 HGNC:4840 HGNC:11491 HGNC:11283 HGNC:4617 HGNC:4616 HGNC:6874 HGNC:6876 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors Respivert Limited 12/30/192D 3D TSV
US10239843 681 620 HGNC:8605 HGNC:270 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG Cancer Research Technology Limited 12/30/192D 3D TSV
US10246425 16 16 HGNC:10593 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds Parion Sciences Inc 12/30/192D 3D TSV
US10246432 25 22 HGNC:4597 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators Heptares Therapeutics Limited 12/30/192D 3D TSV
US10239883 665 132 HGNC:6735 HGNC:4037 HGNC:1133 HGNC:11283 HGNC:6524 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors Merck Sharp & Dohme B.V. 12/30/192D 3D TSV
US10239868 43 43 HGNC:5302 5-hydroxytryptamine receptor 7 activity modulators and their method of use TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 12/30/192D 3D TSV
US10239840 22 22 Benzoazepine derivatives ViiV HEALTHCARE UK LIMITED 12/30/192D 3D TSV
US10238638 48 48 Benzothiazole and benzothiophene compounds Universite de Montreal 12/30/192D 3D TSV
US10245267 2564 1057 HGNC:9829 Biaryl amide compounds as kinase inhibitors Novartis AG 12/30/192D 3D TSV
US10238743 98 49 HGNC:934 HGNC:933 C5-C6-fused tricyclic iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use TBA 12/30/192D 3D TSV
US10239870 462 190 HGNC:3023 Dopamine D3 receptor antagonists Indivior UK Limited 12/30/192D 3D TSV
US10239838 106 53 HGNC:4849 HGNC:4848 Heteroaryl orexin receptor antagonists Merck Sharp & Dohme Corp 12/30/192D 3D TSV
US10246419 13 12 HGNC:7965 Liver X receptor (LXR) modulators RALEXAR THERAPEUTICS, INC. 12/30/192D 3D TSV
US10238633 584 357 HGNC:2528 HGNC:2536 Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C Boehringer Ingelheim International GmbH 12/30/192D 3D TSV
US10239835 142 141 N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B CADENT THERAPEUTICS, INC. 12/30/192D 3D TSV
US10239887 97 75 HGNC:1953 Positive allosteric modulators of the muscarinic acetylcholine receptor M4 Vanderbilt University 12/30/192D 3D TSV
US10239881 26 25 HGNC:10020 RIPK2 inhibitors and method of treating cancer with same University Health Network 12/30/192D 3D TSV
US10239882 86 86 Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors Dart NeuroScience (Cayman) Ltd 12/30/192D 3D TSV
US10239869 405 243 HGNC:10593 HGNC:10597 Sulfonamide compounds as voltage-gated sodium channel modulators LUPIN LIMITED 12/30/192D 3D TSV
US10239861 60 58 HGNC:8638 Therapeutic compounds and uses thereof Genetech, Inc 12/30/192D 3D TSV
US10239876 170 169 HGNC:3020 Triaza-spirodecanones as DDR1 inhibitors Hoffman-La Roche Inc 12/30/192D 3D TSV
US10246426 240 240 HGNC:1395 Triazole compounds as T-type calcium channel blockers IDORSIA PHARMACEUTICALS Ltd 12/30/192D 3D TSV
US10245275 158 76 Triterpenoids with HIV maturation inhibitory activity VIIV HEALTHCARE UK (NO. 4) LIMITED 12/30/192D 3D TSV
US10246429 755 248 HGNC:934 HGNC:2529 HGNC:933 Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use Amgen Inc 12/30/192D 3D TSV
US10227299 295 287 HGNC:1148 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones Bayer Pharma Aktiengesellschaft 12/27/192D 3D TSV
US10233156 57 57 HGNC:85 9-membered fused ring derivative Shionogi & Co., Ltd 12/27/192D 3D TSV
US10233178 24 8 HGNC:6833 HGNC:6834 HGNC:29079 Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use Oryzon Genomics, S.A. 12/27/192D 3D TSV
US10226452 45 45 HGNC:735 Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments University of California 12/27/192D 3D TSV
US10233188 433 221 HGNC:1771 CDK2/4/6 inhibitors Pfizer Inc 12/27/192D 3D TSV
US10227357 1107 650 HGNC:6342 Compounds and methods for kinase modulation, and indications therefor Plexxikon Inc. 12/27/192D 3D TSV
US10231967 323 159 HGNC:620 Compounds and their use as BACE inhibitors AstraZeneca AB 12/27/192D 3D TSV
US10227360 50 49 HGNC:19061 Compounds for use as GPR120 agonists Piramal Enterprises Limited 12/27/192D 3D TSV
US10227329 268 130 HGNC:9967 Compounds useful for treating disorders related to RET BLUEPRINT MEDICINES CORPORATION 12/27/192D 3D TSV
US10227314 13 13 HGNC:2501 Cystathionine-gamma-lyase (CSE) inhibitors SOVA PHARMACEUTICALS, INC. 12/27/192D 3D TSV
US10227373 6 6 Enantiomers of the 1′,6′-isomer of neplanocin A Auburn University 12/27/192D 3D TSV
US10227334 8 8 HGNC:3467 Estrogen receptor modulators and uses thereof Genentech Inc 12/27/192D 3D TSV
US10233187 49 47 HGNC:7967 Fused bicyclic compounds for the treatment of disease AKARNA THERAPEUTICS, LTD. 12/27/192D 3D TSV
US10233189 78 76 HGNC:9967 Fused pyrimidine compound or salt thereof Taiho Pharmaceutical Co., Ltd 12/27/192D 3D TSV
US10227310 6 6 HGNC:32311 Ghrelin 0-acyl transferase inhibitors Eli Lilly and Company 12/27/192D 3D TSV
US10227312 46 46 HGNC:12524 Glucosylceramide synthase inhibitors for the treatment of diseases BioMarin Pharmaceutical Inc 12/27/192D 3D TSV
US10227342 400 99 HGNC:3236 Heteroaryl compounds for kinase inhibition ARIAD Pharmaceuticals Inc 12/27/192D 3D TSV
US10226449 595 337 HGNC:3594 Heterocyclic modulators of lipid synthesis and combinations thereof 3-V Biosciences, Inc. 12/27/192D 3D TSV
US10231957 21 21 HGNC:17071 Histone demethylase inhibitors Celgene Quanticel Research Inc 12/27/192D 3D TSV
US10233190 160 157 HGNC:6059 IDO inhibitors NewLink Genetics Corporation 12/27/192D 3D TSV
US10227341 146 145 HGNC:1133 Inhibiting agents for bruton's tyrosine kinase BIOGEN MA INC. 12/27/192D 3D TSV
US10227327 27 11 Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety Universitetet | Oslo 12/27/192D 3D TSV
US10227343 112 109 HGNC:4596 Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction Vanderbilt University 12/27/192D 3D TSV
US10233152 161 158 HGNC:29079 LSD1 inhibitors Mirati Therapeutics Inc 12/27/192D 3D TSV
US10227331 1137 369 Metallo-β-lactamase inhibitors Merck Sharp & Dohme Corp 12/27/192D 3D TSV
US10231963 109 39 HGNC:8156 Methods for treating depressive symptoms ALKERMES PHARMA IRELAND LIMITED 12/27/192D 3D TSV
US10227346 104 104 Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof Pfizer Inc 12/27/192D 3D TSV
US10227350 167 129 HGNC:8980 Phosphatidylinositol 3-kinase inhibitors Gilead Sciences Inc 12/27/192D 3D TSV
US10227336 32 16 HGNC:4849 HGNC:4848 Pyrazole orexin receptor antagonists Merck Sharp & Dohme Corp 12/27/192D 3D TSV
US10227295 48 24 HGNC:4852 HGNC:14064 Selective histone deactylase 6 inhibitors H. Lee Moffitt Cancer Center and Research Institute Inc 12/27/192D 3D TSV
US10226464 150 75 HGNC:7794 Small molecule NF-κB inhibitors ImmuneTarget, Inc. 12/27/192D 3D TSV
US10233173 647 642 Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators Janssen Pharmaceutica NV 12/27/192D 3D TSV
US10227338 181 136 HGNC:10593 HGNC:10597 Substituted benzenesulfonamides as sodium channel blockers Daewoong Pharmaceutical Co., Ltd. 12/27/192D 3D TSV
US10233160 150 75 HGNC:391 HGNC:10436 Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors Merck Patent GmbH 12/27/192D 3D TSV
US10233182 245 243 HGNC:3357 Substituted spirocyclic inhibitors of autotaxin X-Rx, Inc. 12/27/192D 3D TSV
US10227332 8 4 HGNC:2160 T-type calcium channel modulator and uses thereof UTI LIMITED PARTNERSHIP 12/27/192D 3D TSV
US10233177 25 25 TRPV1 vanilloid receptor antagonists with a bicyclic portion TBA 12/27/192D 3D TSV
US10227340 27 26 HGNC:17967 Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors Bristol-Myers Squibb Co. 12/27/192D 3D TSV
US10227359 58 28 HGNC:13575 Tricyclic heterocycles as bet protein inhibitors Incyte Corporation 12/27/192D 3D TSV
US9872852